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Abstract
Amyloid fibrils have been implicated in numerous human
diseases including Alzheimer's disease (AD). The fibrils found in AD
are formed by the misfolding and aggregation of the Aβ peptide.
Amyloid fibrils are potentially important causative agents, but highresolution structural information is not yet available. This research
analyzes amyloid fibril structure via two different experimental routes.
In one approach, ELISA techniques were utilized to study the binding
of available anti-amyloid antibodies to single-residue proline and
alanine mutant fibrils of Aβ. Binding to some cysteine and modified
cysteine mutants was also tested. These data were compared to fibril
stability, hydrophobicity change, ThT binding, and changes in fibril
protection. There appeared to be no correlation to these, except for
weak correlation to ThT binding. The results at specific residues did
stand out as significant. WO1 and PGA1 binding appeared to be
affected by both charge and structural changes at specific residues.
For WO1, mutations at residues 16, 27, and 28 were shown to have
the greatest impact on binding. For PGA1, mutations at residues 27,
28, 30, 31, and 36 were shown to do so. Upon closer examination,
the enhanced binding to mutants at residues 16 and 36 appeared to
be due to structural changes. Binding to mutants at residue 27 could
ii

be due to structural changes, but these results are not entirely clear.
Binding to mutants at resides 28, 30, and 31 appeared to be due to
charge differences. Binding of WO1 was found to be sensitive to salt
and pH conditions suggesting electrostatic interactions are important
to binding. Mutations in the Aβ sequence have a strong impact on
binding. The basis of these results is still not entirely clear, but they
could be important clues to the nature of fibril structure or the fibril
epitopes recognized by the antibodies. Since the number of existing
antibodies reacting with fibrils is limited, phage display techniques
were employed to develop new binding reagents with a larger range of
binding properties for fibrils. A library of antibody fragments was
constructed in a phage display system and was selected for members
with fibril-binding properties. Although the library was validated, to
date, no suitable antibodies have been isolated.
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Chapter I
Introduction

Alzheimer’s Disease
Amyloid fibrils have been implicated in numerous human
diseases. One of the most prominent of these is Alzheimer's disease
(AD). AD is a neurodegenerative disorder characterized by
progressively worsening dementia. Affected individuals can suffer
among other symptoms: memory loss, difficulty in reasoning,
disorientation, and personality changes. It is the leading cause of
dementia and is the most common neurodegenerative disease [1]. For
the most part, it affects people later in life, though some inheritable
forms can take effect in mid-life and even earlier. Indeed, age is the
greatest risk factor for AD with up to ten percent of people over 65
and up to fifty percent of people over 85 being affected. The
symptoms of AD can be attributed to the extensive neuronal cell death
associated with the disease. This cell death and corresponding loss of
brain function can result in the deaths of affected individuals. An
estimated four million Americans are currently afflicted and millions
more will follow in the coming years [1]. The costs in human suffering
and medical care make AD a grim and far-reaching disease with
disastrous socioeconomic consequences. It is of the utmost
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importance that we continue to make headway in our efforts to fight
the disease. Much is now known about AD, but continuing research
will be required before the effects of the disease can be effectively
curbed.

The onset and advancement of Alzheimer’s disease can be
correlated to the accumulation of the Aβ peptide. It is a 39 to 43
amino acid cleavage product from the amyloid precursor protein (APP)
that can accumulate in the brain. This relationship is supported by the
fact that all genes currently known to be connected to familial AD
influence either Aβ production or deposition [2-4]. Moreover, Aβ(142) and Aβ(1-40) are cytotoxic peptides [5-7]. Some studies indicate
that increasing levels of insoluble Aβ in the brain relative to the soluble
form may be directly related to the development of AD [8]. In
addition, Aβ cytotoxicity has been linked to the ability of the peptide to
aggregate into amyloid fibrils, which can accumulate in deposits in
neural tissue [6]. The form of Aβ found primarily in aggressive, earlyonset AD, Aβ(1-42), is much more prone to aggregation than the (140) species of late-onset AD [6, 9]. This suggests that an enhanced
ability to form amyloid fibrils can lead to a more rapidly progressing
disease state [6]. Furthermore, amyloid fibrils have been shown to be
2

toxic to neurons [10]. This connection between amyloid fibrils, the
ubiquitous indicators of AD found in affected neural tissues, and AD
pathogenesis led to the development of the amyloid hypothesis of AD.
This theory states that it is the buildup of Aβ in amyloid fibrils that
leads to the neural tissue degeneration and pathogenesis of AD [11].
There is much evidence supporting the amyloid hypothesis of AD, but
there is also evidence pointing away from it.

Some studies suggest the fibrils themselves may not be the
direct cause of AD pathogenesis [12]. Bearing in mind that insoluble
Aβ appears to take part in AD pathogenesis, it may be that other
insoluble Aβ species besides amyloid fibrils are at fault. Amyloid fibril
intermediates may actually be responsible for AD pathogenesis [13].
These intermediates include spherical particles as well as protofibrils
[14-16]. They may be precursors in the formation of amyloid fibrils
[14, 16] or they may be the products of distinct assembly pathways
[14]. The protofibrils are of particular interest since there is some
evidence suggesting these may be the toxic species. For instance, the
‘Arctic’ APP mutation associated with a particular familial form of AD
has been shown to lead to increased protofibril formation and stability,
but not increased fibril formation [17]. Because of the possible role of
3

protofibrils in AD pathogenesis, they will be further explored within a
discussion of amyloid fibrils.

Amyloid Fibrils
Amyloid fibrils were first discovered in human neural tissue and
reported by Virchow in 1851 [18]. The name amyloid is a misnomer
stemming from the fact that a starch staining technique was originally
used to stain the fibrils. The word “amyloid” actually means starchlike. Virchow used the iodine and sulfuric acid technique for staining
starches and found that the fibrils stained similar to cellulose [19].
Though we now know the fibrils are made up of proteins, the name
amyloid remains in use. Since that initial discovery, more refined
techniques have been developed for staining and detecting amyloid
fibrils.

Congo Red staining was a significant development to that end.
This dye was found to be a specific and sensitive detector of amyloid
fibrils by Bennhold in 1922, as it stains the fibrils a bright red [20]. It
was later discovered by Divry and Florkin that polarizing optics could
be used to observe amyloid fibrils [21]. With this technique, otherwise
inconspicuous amyloid deposits in tissue samples can be detected
4

since they show birefringence. That is, the fibrils have a regular,
ordered structure capable of altering the phase of incident light
passing through them. By combining these two techniques, using
polarizing optics on fibrils stained with Congo Red, it was found that
amyloid fibrils have a distinctive green birefringence [22]. The red
color exhibited by the dye shifts to green under polarizing optics.
Other than the obvious utility this technique provides, it also
emphasizes that amyloid fibrils are not amorphous aggregates, but
rather highly organized structures.

There are many amyloid diseases and conditions in which
amyloid fibrils are present. The proteins responsible for the fibrils vary
from one disease to the next. In fact, there are at least 20 different
proteins found in humans that are reported to form amyloid fibrils
[23]. Though the fibrils in each amyloid disease are composed of
different proteins, they share many structural characteristics common
to all amyloid fibrils. Cohen and Calkins revealed through electron
microscopy studies that amyloid fibrils of many different proteins share
a number of common characteristics at the macro scale. The fibrils
are highly insoluble, rigid, nonbranching, and of variable lengths up to
several µm [22, 23]. They are in the vicinity of 8 to 10 nm in
5

diameter and are likely made up of two or more protofilaments
running in parallel and twisted about one another. These are in the
range of about 3 nm in diameter. Protofilaments and protofibrils are
separate, distinct species. Protofibrils have been found to be curved
fibers 3 to 10 nm wide and up to 200 nm in length [14, 16, 24]. They
do not approach the lengths reached by amyloid fibrils and are not
subunits of these fibrils.

X-ray fiber diffraction studies were later conducted on a number
of different amyloid fibrils to probe the amyloid superstructure. These
revealed that amyloid fibrils exhibit a cross-β conformation. That is,
the fibrils are rich in β-sheet structure and the β-strands run
perpendicular to the fibril axis. In this conformation, the β-strands are
hydrogen-bonded into β-sheets lying parallel to the fibril axis (Figure
1). This particular conformation appears to be rare in nature and is
more typical of denatured proteins [22]. It has been shown that some
insect silks exhibit the cross-β conformation, but their β-strands
usually run parallel to the fibril axis [22]. A comparison is shown in
figure 1. Perpendicular β-strands are generally reserved to amyloid
fibrils. Protofibrils have also been found to be rich in β-sheet structure
[13, 25]. This is a brief review of our collective knowledge of amyloid
6

Figure 1. The cross-β conformation. In amyloid fibrils, β-sheets
lie parallel to the fibril axis. These are composed of β-strands running
perpendicular to the fibril axis. In comparison, insect silks with crossβ structure possess β-strands running parallel to the fibril axis [22].
The β-strands are shown forming β-sheets on the front faces of the
fibrils in the diagram. One strand is bold and highlighted in red on
each fibril.
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fibrils. As previously mentioned, these fibrils are found in many
human diseases.

Other Amyloid Diseases
The amyloidogenic protein in each amyloid disease is unique.
Furthermore, the means by which each becomes amyloidogenic can
differ. The role of the fibrils in each disease, when it is known, can
also differ from one disease to the next. A few examples of diseases
other than AD marked by the presence of amyloid fibrils are familial
amyloid polyneuropathy (FAP), secondary amyloidosis, and type II
diabetes. These represent a small cross-section of diseases in which
amyloid fibrils are found. Briefly looking at each should provide some
insight into the diverse nature of amyloid diseases.

The culprit protein in FAP is transthyretin (TTR), which is
normally responsible for transporting retinol-binding protein in addition
to thyroxine. Certain mutations in the TTR protein destabilize it such
that the normally soluble protein can misfold and become prone to
aggregation [26, 27]. The fibrils of TTR can accumulate in many
different tissues, but often end up in the heart where the deposits can
lead to congestive heart failure. More stable variants of TTR can also
8

aggregate into amyloid fibrils in the heart, but in these cases the
impact is less severe and the age of onset is later in life [26]. Many
other diseases can be tied to mutations in fibril-forming proteins [27].
These include familial early-onset AD, Creutzfeldt-Jakob disease, and
several others.

Secondary amyloidosis is a condition that occasionally arises in
response to extended or severe inflammation. In this disease, the
amyloidogenic protein is amyloid A (AA), a proteolytic product of the
circulatory precursor serum amyloid A (SAA) [26]. Fibrils of AA are
deposited mainly in the spleen, kidneys, and liver where they can
cause organ failure. In secondary amyloidosis, severe inflammation
and tissue damage lead to ramping of SAA production up to 1000 fold
of basal levels. It is not known exactly what drives the conversion of
SAA to AA leading to the deposition of AA fibrils. However, it has been
suggested that the disease state results from an inability to clear the
excess protein [26]. Another amyloid condition marked by protein
overproduction is light chain amyloidosis [26].

An example of amyloid as a secondary component of a disease
occurs in type II diabetes. The central problem in this disease is
9

insulin underproduction and insulin resistance leading to dangerously
elevated blood glucose levels. The amyloidogenic protein is islet
amyloid polypeptide (IAPP), which is normally released into the
bloodstream concurrently with insulin to regulate blood glucose levels
[26, 28]. In type II diabetes, IAPP can aggregate into amyloid fibrils
that are deposited in the pancreas where they can lead to the
destruction of insulin-producing β-cells. These fibrils can then
exacerbate the pathology of this disease by further hampering insulin
production.

It is clear that amyloid fibrils are pervasive in many human
diseases. They are not always the defining characteristic of a given
disease, such as in type II diabetes, but their impact is nonetheless
significant and destructive. Moreover, the constituent proteins in each
are varied both in their amino acid sequences and in the causes of
their amyloidogenicity. Amyloid fibrils have been under scientific
scrutiny for some time and continue to be studied. In the history of
amyloid research, many important findings have been made to
establish a body of knowledge about these fibrils.

Little detailed

information about a common amyloid fibril structure is available.
However, much more is known about the proteins and peptides that
10

misfold to form those fibrils. The peptide responsible for AD amyloid
fibrils, Aβ, has been thoroughly studied. The fibrils found in AD are
composed primarily of misfolded and aggregated Aβ peptide. We have
learned a bit more specifically about these fibrils. Before discussing
them, it is first helpful to have a basic understanding of the Aβ
peptide.

The Aβ Peptide
The Aβ peptide is a cleavage product from the APP, which is a
large transmembrane protein found on the surfaces of cells in many
different tissues. The exact functions of APP have not yet been
established. Furthermore, it has been shown that deletion of the APP
gene in mice does not cause early death or a serious disease state
[29]. It is possible that this could be due to the existence of several
mammalian homologs to this gene [29]. In any case, APP is
evolutionarily conserved and expressed in all mammals. This suggests
it serves an important role [29]. There are numerous isoforms of APP
that arise from alternative splicing of the APP gene. Some such as the
751 and 770 amino acid isoforms are found in numerous cell types
while others such as the 695 amino acid isoform are found
predominantly in neuronal cells. There is also added variation due to
11

several post-translational modification of APP [9, 29]. APP metabolism
is still further complicated by variable proteolytic cleavage of the
extracellular domain. Though the whole of APP metabolism is quite
complicated, we are focused only on the products of proteolytic
cleavage.

APP can be cleaved at specific sites by the α-, β-, and γsecretases (Figure 2). First, either α-secretase cleaves 12 residues out
from the membrane-spanning domain or β-secretase cleaves 28
residues out. This releases the large soluble α- or β-APPs domains,
respectively. Only when β-secretase cleavage has occured can γsecretase cleavage result in the Aβ peptide. γ-secretase cleaves about
12 to 14 residues into the membrane-spanning domain, releasing the
Aβ peptide [9]. These alternate cleavage patterns are shown in figure
2. The peptide can range in length from 39 to 43 residues [30]. The
43 residue sequence is shown in figure 3. The 40-residue variant is
that most commonly found in amyloid fibrils. A number of studies
have been conducted on these particular amyloid fibrils.
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Figure 2. APP metabolism. In this example, a 770 residue isoform
is used. Cleavage by β-secretase at position 671 followed by γsecretase at position 711 to 713 yields the Aβ peptide [9]. (Adapted
from Selkoe, D.J., Amyloid beta-protein and the genetics of
Alzheimer's disease. J Biol Chem, 1996. 271(31): p. 18295-8.)

Figure 3. The Aβ(1-43) amino acid sequence. In the 40-residue
variant, the amyloid core extends roughly from the vicinity of residue
15 to that of residue 36. The remaining amino- and carboxy-terminal
residues are solution accessible and are not involved in protected βsheet structure [31-34].

13

Aβ Amyloid
Limited proteolysis and hydrogen-deuterium (HD) exchange
studies on the 40-residue isoform of Aβ in amyloid fibrils have shown
the presence of a stable core [31-33]. The remainder of the peptide is
exposed to digestion and HD (hydrogen-deuterium) exchange. Only
about half of the residues of the Aβ peptide are involved in protected
β-sheet structure in this core. The remaining residues at the aminoand carboxy-terminal ends of the peptide are not involved and are
accessible to solvent. These regions span the first 13 to 16 residues at
the amino terminus and the last 4 residues at the carboxy terminus
[32, 34]. Aβ protofibrils also possess a protected core, though the
degree of protection is less [13]. This suggests that protofibril
structure may be similar to that of fibrils. The presence of a stable
core in amyloid fibrils is further supported by stability studies on fibrils
of single proline mutants of Aβ [34].

Scanning proline mutagenesis was used in conducting these
experiments [34]. This technique entails generating single proline
mutants at each position in the Aβ sequence and growing fibrils from
the mutants to be analyzed [34, 35]. These mutants can be very
informative since the rigid nature of proline and the fixed angle bend it
14

imparts to the peptide can have a significant impact on a given protein
structure. Prolines are expected to have little impact on unstructured
regions and less impact on turn regions when compared to that on βsheets [34]. In fact, prolines are not usually found in amino acid
sequences involved in β-sheet structure where they appear to be
highly disfavored [34, 36, 37]. Prolines are more amenable to
unstructured regions and turns that are capable of incorporating the
rigid amino acid without being distorted. For these reasons, prolines
are expected to destabilize fibrils when inserted into positions involved
in β-sheet structure [34].

Fibrils from mutant peptides with proline in the amino- and carboxyterminal regions share, for the most part, stabilities similar to those of
wild-type fibrils. Fibrils from mutants in the core sequence are
destabilized to varying degrees [34]. It is the amyloid core that is
involved in fibril formation and the protected nature of it once
incorporated into fibrils highlights the stability of amyloid fibrils. In
addition to the residues involved in fibril formation, more is known
about Aβ amyloid fibrils. This information has been applied to build a
model of amyloid fibril structure. Our model describes the structure of
Aβ protofilaments, the constituents of Aβ amyloid fibrils. It is based
15

on the aforementioned data, particularly the scanning proline
mutagenesis and fibril stability results [34]. The model is shown in
figure 4. It predicts a tightly packed amyloid core with the
unstructured, solvent accessible amino- and carboxy-terminal regions
projecting out from it. It is not certain that these regions are
unstructured, but their high degree of solvent accessibility suggests
they are not involved in the tightly packed and protected β-sheet
structure of the amyloid core [31-33]. With that said, the core is the
focus of the model.

The model is organized as a parallel β-helix, a structure
consisting of β-strands coiling down its length and forming β-sheets
between parallel β-strands [34]. In the model, the Aβ rungs are
stacked in register down its length [34]. Each Aβ subunit within
contains three β-strands separated by two turns forming roughly a
triangle (Figure 4). The turns are in the vicinity of residues 22 to 23
and 29 to 30 resulting in three β-strands that are 5 to 7 residues in
length: 15-21, 24-28, and 31-36. The core β-sheet structure ends in
the region of residues 15 to 16 and 36 to 37. From these regions, the
solvent accessible amino- and carboxy-termini extend out from the
core. This model aims to describe the structure of Aβ amyloid fibrils,
16

Figure 4. Aβ amyloid protofilament model. Aβ monomers are
stacked down the length of the filament with residues 1-14 and 37-40
extending in disorder out from the amyloid core. Residues 15-21, 2428, and 31-36 comprise β-strands. Residues 22-23 and 29-30
comprise turn regions [34]. (Adapted from Williams, A.D., et al.,
Mapping abeta amyloid fibril secondary structure using scanning
proline mutagenesis. J Mol Biol, 2004. 335(3): p. 833-42.)
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though it is not set in stone. As further research is conducted, the
model will continue to grow and evolve. The research presented here
represents an effort to further our understanding of amyloid fibril
structure. Towards that goal, ELISA techniques have been used to
study the binding of anti-amyloid antibodies to amyloid fibrils.

Anti-amyloid Antibodies
There are several anti-amyloid antibodies available in our lab
[40]. They are all of the IgM class, a pentameric species with ten
antigen-binding sites and a molecular weight of around 900 kDa [38].
IgM antibodies are the products of the primary immune response.
They are the first antibody species produced in response to a given
antigen. Production of antibodies of other classes, including IgG,
requires a class switch event involving gene rearrangements to take
place [38]. IgG antibodies are the products of the secondary immune
response after the class switch event. The IgM molecule is composed
of five IgG-like subunits [38]. A diagram of the IgM molecule is shown
in figure 5e. The subunits resemble IgG molecules in structure (Figure
5a). Each subunit possesses one µ heavy chain and one light chain
held together by disulfide bonds. The heavy chain contains four
constant domains, CH1 through CH4, and one variable domain, VH
18

Figure 5. Major immunoglobulin classes. IgM class antibodies (e)
are pentameric species when compared to IgG class antibodies (a).
They possess ten binding sites compared to two for IgG molecules
[38]. (Adapted from Kuby, J., Immunology. 3rd Edition ed. 1997.)
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(Figure 5e). The light chain contains one constant domain, CL, and
one variable domain, VL (Figure 5e). The IgG-like subunits are held
together by disulfide bonds and additionally by a small polypeptide
called the J chain between two of the subunits (Figure 5e). Each of
the ten antigen-binding sites is comprised of six complementarity
determining regions (CDRs) looping out from the two variable
domains, three from the heavy chain and three from the light chain
[39]. These loops are responsible for antigen binding and amino acid
differences between them provide for binding diversity. In IgM
molecules, the multiple binding sites can bind cooperatively to an
antigen provided there are a sufficient number of target sites on the
antigen. Because each binding site contributes to the overall affinity,
its individual affinity need not be as strong. This is the avidity effect.
In the case of amyloid fibrils, the apparently regular, repeating
structure could potentially accommodate multivalent binding [40].
The avidity effect may be important to amyloid binding. This may
explain why, to date, we have only obtained IgM antibodies.

Two well-studied anti-amyloid antibodies are WO1 and WO2,
isolated by Dr. Brian O’Nuallain [40]. These antibodies possess κ light
chains. They have been shown to possess germ-line sequences by
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sequence analysis (Kimberly Salone, unpublished data). That is, the
WO1 and WO2 sequences are made up of genes already encoded in
the genome and contain variable regions that have not been altered by
somatic mutation. The antibodies were isolated from mice immunized
with Aβ amyloid fibrils. Monoclonal antibodies were selected so that
they bind only amyloid fibrils and not Aβ monomer. This was done by
carrying out binding to immobilized Aβ amyloid fibrils in the presence
of soluble Aβ monomer. The antibodies were isolated from highdensity mouse myeloma cultures. These antibodies also bind amyloid
fibrils other than Aβ including amyloids from immunoglobulin light
chain, transthyretin, and β2-microglobulin. This binding of different
targets by the antibodies is very unusual and supports the notion of a
common structural motif among all amyloid fibrils. Furthermore, the
apparent structural specificity makes these antibodies very useful in
studying amyloid structure. WO1 has recently been shown to bind Aβ
protofibrils as well (Dr. Merav Geva, unpublished data). This result
coupled with the other characteristics shared between amyloid fibrils
and protofibrils indicates that these two species may be structurally
related. A study of amyloid fibril structure may provide some insight
into protofibril structure as well.
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There are limits in the use of the anti-amyloid antibodies. A
major limitation is that all of these anti-amyloid antibodies are of the
IgM class. Since these are large, flexible, multivalent species, they are
poorly suited for many structural studies. For instance, no IgM
molecules have yet been crystallized. Due to such limitations, another
goal of this thesis work has been to generate novel anti-amyloid
antibodies more suitable for these studies. To this end, phage display
techniques have been applied.

Phage Display Principles
For our study, phage display was used to generate amyloidspecific Fab antibodies more amenable to structural work. Phage
display is a powerful technique that can be used for the affinity
selection of specific proteins or peptides out of a massive library. Such
a library can exceed sixty billion unique peptides or antibody forms
allowing for sampling of a broad range of potential binders to a given
target. Furthermore, the selection process is much faster than
traditional hybridoma screening and can be completed in a relatively
short period of time [41]. Phage display involves two major steps.
The first step is the expression of a library of proteins or peptides as a
fusion protein with one of the phage coat proteins. This results in a
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phage library whose constituents each have mutant proteins or
peptides expressed on its coat. The number of copies depends on the
phage display system used. The second is the affinity selection of the
phage library for a given target. Phage expressing proteins or
peptides with high affinity for the substrate can be separated from
those with low or no affinity simply by binding the phage to the target
and washing away unbound phage. In order to better understand
exactly how this process works, one must first understand the M13
bacteriophage that is used in phage display experiments.

The M13 bacteriophage is a filamentous phage that infects E. coli
by interacting with the F pili found on F+ cells through its five tail
fibers. It is used in phage display for several reasons. The structure
and life cycle of M13 are well understood [42]. It is easy to work with
and manipulate as is the host, E. coli. It does not kill the cells after
infection, but only slows their growth, allowing production of large
amounts of phage by simply culturing infected cells. The phage
particles are extremely hardy, resistant to low and high pH as well as
other denaturants. Several of the phage coat proteins will tolerate the
addition of sequences of peptides or small proteins without disruption
of their structures or that of the phage particle [41]. This is key to the
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phage display technique. When DNA is added to the phage genome
making it longer, the phage particle simply incorporates more of the
major coat protein to encompass the added DNA inside the phage
filament [41]. The M13 phage is a robust and versatile tool that can
easily be manipulated for use in phage display experiments. A
discussion of the phage structure and life cycle will shed more light on
these advantages and on the inner workings of the phage display
technique.

The M13 phage particle consists of a protein coat encapsulating
a circular single-stranded DNA (ssDNA) genome. The genome encodes
the genes for eleven proteins, five of which comprise the phage coat
and five of which are nonstructural proteins involved in viral
replication. Gp8 is the 5kDa major coat protein with about 2700
copies per wild-type phage particle (Figure 6, top). It serves to
encapsulate the phage genome. Five copies each of gp3 and gp6 are
found at one end of the particle and five each of gp7 and gp9 at the
other. Gp3, the tail fiber protein, and gp6 are involved in the infection
process. Gp7 and gp9 recognize a packaging signal in the phage
genome and are necessary for formation of the mature phage particle
[42]. Any of these proteins can be modified with the addition of a
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Figure 6. A diagram of the M13 bacteriophage. The phage
protein coat encapsulating the phage genome is shown at the top. In
the bottom left is a subdomain breakdown of the gp3 coat protein, also
called pIII. Gp3 consists of three domains separated by flexible
glycine-rich linkers: the amino terminal domain (N1), the middle
domain (N2), and the carboxy-terminal domain (CT) [41]. (Adapted
from Barbas, C.F., 3rd, et al., Phage Display: A Laboratory Manual.
2002.)
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sequence to be displayed, but each coat protein has limitations as to
how it can be modified [41]. Gp3 is the most commonly modified coat
protein in phage display experiments and presents the fewest
complications. Gp3 was modified for this work.

Gp3 consists of three domains separated by flexible glycine-rich
linkers: the amino terminal domain (N1), the middle domain (N2), and
the carboxy-terminal domain (CT) (Figure 6, bottom). N1 and N2 are
involved in the process of viral infection while CT is involved in phage
coat structure [42]. Any of the three can be deleted or modified for
phage display experiments, however CT is typically not modified due
to the potential for disruption of phage coat structure [41]. N1 was
replaced with the mutants for this work. The domain replacement
effectively eliminates the ability of the transgenic gp3 to be involved in
the infection of a bacterial host. If all five copies of gp3 were
modified, the phage would be incapable of infecting the bacterial host.
This is a problem when it comes to proliferation of the selected mutant
phage. It is dealt with by the use of phagemid vectors and helper
phage.
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Phagemid vectors are phage genomes propagated in the form of
plasmids that contain a number of modifications. They possess only
the transgenic phage coat protein gene and none of the other ten
genes (Figure 7, top left). Phagemid vectors, therefore, cannot direct
the production of phage particles on their own. They possess the M13
origin of replication and a functional phage-packaging signal just as
wild-type phage. They also have a bacterial plasmid origin of
replication and an antibiotic resistance marker. This plasmid structure
allows phagemid amplification in E. coli cells and selection for
transfected cells via an antibiotic. When phagemid vectors are
transformed into E. coli cells, they are replicated as plasmids and do
not induce the production of phage particles [41]. Helper phage must
be introduced to help production of phage particles.

Helper phage are essentially wild-type phage capable of normal
infection all but for a few important differences. They have drastically
reduced proliferation potential due to an altered phage-packaging
signal that is poorly recognized during phage assembly. Helper phage
particles can still be produced, albeit at a much slower rate and titer
than phage with wild-type packaging signals. When E. coli carrying
phagemid vectors are infected with helper phage, they express
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Figure 7. A diagram of phagemid display. E. coli cells infected
with the phagemid are coinfected with helper phage. The phagemid
only provides the one capsid protein gene, which is a fusion with a
displayed protein gene. The helper phage genome provides all the
other genes necessary to produce phage particles. It also provides the
nonmutant form of the gene present in the phagemid. These result in
chimeric phage particles, with proteins encoded by both the phagemid
and helper phage genome [41]. (Adapted from Hoess, R.H., Protein
design and phage display. Chem Rev, 2001. 101(10): p. 3205-18.)
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proteins from both types. Since the helper phage carry a different
antibiotic resistance marker than the phagemid vectors, kanamycin in
the case of the VCSM13 helper phage, E. coli cells can be selected for
possession of both markers. This prevents the uninfected cells from
out-competing the slower growing helper phage infected cells. The
helper phage genome guides the production of all the necessary phage
proteins while the phagemid genomes produce the transgenic tail fiber
proteins. This results in the production of chimeric phage particles
(Figure 7, bottom). Either a phagemid vector or a helper phage
genome will be packaged into each phage particle. Since the helper
phage genome has a substantially reduced capacity to be packaged
into phage particles, the vast majority of the particles will contain
phagemid vectors. Moreover, each will bear a combination of
transgenic and wild-type copies of the altered coat protein. There are
five copies of gp3 per phage particle, part of which will be transgenic
and the rest wild-type. The number of copies of each can be
controlled somewhat by adjusting the ratio of infecting helper phage to
phagemid vectors present in the cells. The ratio can be skewed
tremendously towards helper phage so most of the phage particles
contain either one copy or no copies of the transgenic gp3. The
particles with no copies of the transgenic gp3 are of no value, but they
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can be selected against so they are likewise not a burden. However,
the particles with one copy will present the transgenic gp3 while
retaining infectivity since they have four copies of wild-type gp3 [41].
Having discussed how the M13 bacteriophage and its variants, the
phagemid vector and helper phage, function in a phage display
system, it is next important to discuss how a library of phagemid
vectors is generated.

A cDNA library of mutants must be generated before phage
display experiments can be carried out. This can be done with some
form of random mutagenesis on a starting cDNA sequence. Error
prone PCR is one method that can be used. This technique is simply a
PCR reaction of the sequence using conditions that result in random
base substitutions. It relies on the use of different concentrations of
manganese and skewed dNTP concentrations in the PCR reaction to
increase the frequency of these mutations. The specific PCR conditions
used will be discussed later. Once the population of mutant cDNA
sequences is acquired, it must be cloned into the M13 phage genome
as part of one of the phage coat protein genes. This process will be
discussed in detail later.
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The phage particles produced through phagemid display present
the mutant proteins or peptides on their coats. They can be selected
for the ability of the displayed mutant to interact with a specific
substrate. Furthermore, since the phage particles contain the DNA
sequences of the mutants, the binding ability of each phage can be
coupled to the mutant DNA sequence it possesses. Therein lies the
power of phage display. Because the binding ability is associated with
the DNA sequence, mutant genes coding for strong or weak binders
can easily be isolated, amplified, and characterized. This can be done
entirely without any special knowledge of the target or the means by
which the mutants may bind it. Phage display does not depend on a
knowledge of the intricacies of binding. It simply samples through a
huge library of possibilities to find those that have the desired
properties. This is a boon to studies involving poorly characterized or
difficult to study substrates and it allows phage display to cover broad
swathes of sequence space quickly and cheaply.
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Chapter II
Methods

There is little detailed information available about a common
amyloid fibril structure. We are left with the only concrete information
being the macroscopic structural cues. There is somewhat more
known about Aβ amyloid fibrils, but a detailed molecular structure
remains elusive. A working model of Aβ amyloid has been developed
[34], but further investigation is required to test that model. The work
described herein aims to probe deeper into amyloid fibril structure by
studying the binding properties of anti-amyloid antibodies.

Section 1. Anti-amyloid Antibodies
Determining Antibody Binding Properties
ELISA techniques were used for determining antibody binding
affinity to amyloid fibrils. An ELISA experiment involves coating the
wells of a polystyrene assay plate with a target antigen and
determining if or how strongly a particular antibody binds to the
antigen. This is done by first incubating the coated plate with the
antibody in question, the primary antibody.

The plate is next

incubated with a secondary antibody that binds to the primary
antibody. The secondary antibody is a conjugate that provides for a
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means of detection. Biotinylated secondary antibodies were used in
this protocol. These will bind streptavidin-conjugated molecules.
Streptavidin-Europium was used as the labeling agent for detection of
anti-amyloid antibodies binding to substrates. Time-resolved
fluorescence was used for detecting the Europium. This technique
relies on the very long lag time between the excitation and
fluorescence of Europium. By the time Europium fluoresces,
background fluorescence from most all other compounds has decayed.
Europium also exhibits a large Stokes shift with the excitation and
emission wavelengths of Europium at 340 and 615 nm, respectively.
These qualities make Europium a very sensitive and specific vehicle for
detection. The ELISA techniques used in these experiments have been
well established [40]. A diagram of the ELISA protocol is shown in
figure 8.

In brief, 96-well high-binding polystyrene ELISA plates with flatbottom wells (Corning/Costar) were coated using 50 to 100 ng of Aβ
amyloid fibrils or other aggregates per well. The fibrils were
suspended in 50 µL of 1xPBS (Fisher, Appendix I) in each well. A
working suspension of 1 µg/mL to 2 µg/mL of the fibrils was prepared
for coating the plates. Two plate columns were coated for each
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Figure 8. A diagram of the ELISA protocol. This figure shows one
ELISA plate well. Plates coated with amyloid fibrils are incubated with
a primary antibody, a biotinylated secondary antibody, and then
streptavidin-Europium. An enhancement solution is added to the wells
and the plate is read.
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dilution series (Figure 9). The plates were incubated overnight at
37°C uncovered to allow the solutions to dry in the wells.

The plates were washed 2 times with ELISA wash buffer
(Appendix I) to remove dried salts and unbound fibrils. To block the
plates, each well was filled with 250 µL of ELISA blocking solution
(Appendix I). The plates were covered with plate sealers (Costar) and
incubated at 37°C for 1 hour. The plates were emptied and 100 µL of
ELISA blocking solution was pipeted into each well. A 400 to 800 nM
solution of the antibody to be tested was prepared in ELISA blocking
solution. 100 µL of the antibody preparation was transferred into well
A1, making 200 µL in total in the well, and pipeted up and down 4
times to mix (Figure 9). This process was continued down column 1,
then from well H1 to well A2, and down thru well F2. For each step,
100 µL of the mixture was transferred to the next well in the series
and mixed as before. The remaining 100 µL at the end of each dilution
series was discarded. The last 2 wells of each dilution series were left
with only ELISA blocking solution in them. This process generates a
dilution series decreasing by a factor of 2 per well, with the last 2 wells
providing background readings since they contain no primary antibody.
Readings from the last two wells are subtracted from the others to
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Figure 9. ELISA plate layout. Dilution series are set up down pairs
of columns. An example dilution series in columns 1 and 2 would
begin with the highest concentration in well A1. Each well down the
column would have one half the concentration of the previous well.
The series would continue from well H1 to well A2 and down through
well F2. The last 2 wells would be left without the substrate to provide
background readings.
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remove background binding of the secondary antibody and
streptavidin-Europium from the affinity calculation. The process was
repeated for each dilution series. The plates were covered with plate
sealers and incubated at 37°C for 1 hour. When buffer effects on
binding were to be analyzed, the appropriate buffers were used in
place of ELISA blocking solution for the primary antibody-binding step
(Table 1). For the remainder of the protocol, ELISA blocking solution
was used in all cases.

The plates were washed 2 times with ELISA wash buffer. A
1:5000 dilution of the secondary antibody, biotinylated goat antimouse IgM (µ-chain specific, Sigma), was prepared in ELISA blocking
solution. 100 µL was pipeted into each well. The plates were covered
with plate sealers and incubated at 37°C for 40 minutes. The plates
were washed 2 times with ELISA wash buffer. A 1:1000 dilution of
Delfia Europium-labeling streptavidin (Perkin Elmer) was prepared in
ELISA blocking solution. 100 µL was pipeted into each well. The
plates were covered with plate sealers and incubated at room
temperature in the dark for 1 hour. The plates were washed 3 times
with ELISA wash buffer. 100 µL of Delfia enhancement solution
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Table 1. Buffers for salt and pH effects experiments. All buffer
compounds except citric acid were ordered from Calbiochem. The first
3 buffers in the table were used for testing the effects of the amount
of salt. The first 5 buffers excluding the third were used for testing the
effects of different cations and anions. HEPES is a buffer of very low
ionic strength, so it should not interfere greatly with comparing the
different salts. Na2HPO4 has roughly double the ionic strength of the
other 2 salts so it was used at half the concentration for a balanced
comparison. The last 8 buffers were used for testing pH effects.
Buffer compound
5 mM HEPES
5 mM HEPES
5 mM HEPES
5 mM HEPES
5 mM HEPES
5 mM citric acid
5 mM citric acid
5 mM PIPES
5 mM PIPES
5 mM Bicine
5 mM Bicine
5 mM CHES
5 mM CHES

Salt
150 mM NaCl
600 mM NaCl
150 mM KCl
75 mM Na2HPO4
150 mM NaCl
150 mM NaCl
150 mM NaCl
150 mM NaCl
150 mM NaCl
150 mM NaCl
150 mM NaCl
150 mM NaCl
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pH
7.5
7.5
7.5
7.5
7.5
3.0
5.8
5.8
7.4
7.4
8.5
8.5
10.0

(Perkin Elmer) was pipeted into each well. The enhancement solution
chelates Europium from the complexes and into solution for detection.
A Wallac Victor2 1420 Multilabel Counter was used for detection. Each
reading was taken for 400 µs after a 400 µs delay (Perkin Elmer).

The binding data were analyzed using Microsoft Excel and
plotted as sigmoid curves in Kaleidagraph. The fluorescence counts for
each assay were all divided by 4,800 counts/fmol to obtain the
femtomoles of Europium in each well. These values were plotted
against –log10(antibody concentration) at each point to obtain sigmoid
curves (Figure 10). Two key features of these curves are the
magnitude and the midpoint of the sigmoid curve (Figure 10). The
magnitude is indicative of the number of available antigen binding
sites while the midpoint tells the affinity of the antibody for the
antigen.

After preparing the binding data as described, it was plotted in
Kaleidagraph against log10(antibody concentration). Sigmoid curve fits
were obtained using equation 1 in Kaleidagraph. The binding affinity
from each curve was obtained from the inverse log of the x value at
the midpoint (10^m1) after fitting the sigmoid curve in Kaleidagraph
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Figure 10. An example of ELISA data. These curves show the
binding of WO1 to Aβ amyloid (open circles), fibrils of antibody light
chain (JTO5, closed squares), and a control IgM (open triangles) [40].
The midpoint of the Aβ amyloid sigmoid is denoted by the red lines.
The binding affinity is obtained by getting the inverse log (10x) of the x
value at that point. (Adapted from O'Nuallain, B. and R. Wetzel,
Conformational Abs recognizing a generic amyloid fibril epitope. Proc
Natl Acad Sci U S A, 2002. 99(3): p. 1485-90.)
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(Equation 1). The binding affinity is the antibody concentration at
which one half maximal binding is reached. This value is reported as a
molar concentration (M).
y = m3 / (1 + e^((m1 – m0) / m2)). Equation 1.
This equation was entered into Kaleidagraph. The starting
values were: m1 = 1, m2 = 1, and m3 = 20. After the best fit
sigmoid was calculated in Kaleidagraph, values were returned for
m1, m2, and m3. The midpoint x value of the sigmoid was
reported in m1, the slope of the tangent line to the midpoint was
reported in m2, and the magnitude of the sigmoid was reported
in m3. For determining antibody binding affinity, m1 was used.
All 3 values were used for concentration determination
calculations.

Determining Antibody Concentration
ELISA techniques were used for determining antibody
concentration. The protocol shares many similarities with that for
determining binding affinity, but there are several important
differences. The purpose was to determine concentration rather than
binding activity, so the ELISA plate was coated with a capture antibody
rather than amyloid fibrils. The antibodies whose concentrations are
to be tested are diluted significantly and all to the same level as a
standard antibody of known concentration. The capture antibody will
bind these antibodies to the plate with very high affinity. From this
stage on, the protocol was the same as that for determining binding
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activity. After the protocol is completed, the concentrations of the
unknowns are calculated relative to the known standard.

For this protocol, 96-well high-binding polystyrene ELISA plates
with flat-bottom wells (Corning/Costar) were used. They were coated
using a 1:1000 dilution of a capture antibody, goat anti-mouse IgM (µchain specific, Sigma). 50 µL was pipeted into each well. Two
columns were coated for each antibody to be assayed along with an
additional 2 columns for a control antibody. The plates were covered
with plate sealers and incubated at 37°C for 1 hour. They were
washed 2 times with ELISA wash buffer. To block the plates, each well
was filled with 250 µL of ELISA blocking solution. They were covered
with plate sealers and incubated at 37°C for 1 hour.

The plates were emptied and 100 µL of ELISA blocking solution
was pipeted into each well. 1:100 dilutions of the antibodies to be
tested were prepared in ELISA blocking solution. Likewise, a 1:100
dilution of the standard antibody was prepared. If any of the resulting
data sets did not produce a complete sigmoid curve, the initial dilution
was adjusted when repeating the experiment. Mouse IgM
(Calbiochem) was used as the standard since the unknowns were
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mouse IgM antibodies. It is imperative that the concentration of the
standard antibody be known since it is later used in calculating the
concentrations of the antibodies of interest. 100 µL of the antibody
preparation was transferred into well A1, making 200 µL in total in the
well, and pipeted up and down 4 times to mix (Figure 9). This process
was continued down column 1, then from well H1 to well A2, and down
thru well F2. For each step, 100 µL of the mixture was transferred to
the next well in the series and mixed as before. The remaining 100 µL
at the end of each dilution series was discarded. The last 2 wells of
each dilution series were left with only ELISA blocking solution in
them. This process generates a dilution series starting at a 1:200
dilution and decreasing by a factor of 2 per well with the last 2 wells
providing background readings since they contain no primary antibody.
The process was repeated for each antibody including the standard
antibody. The plates were covered with plate sealers and incubated at
37°C for 1 hour. The remainder of the protocol is already described
under the heading ”Determining Antibody Binding Properties” starting
at the secondary antibody incubation step.

The resulting data were analyzed using Microsoft Excel and
plotted as sigmoid curves using Kaleidagraph. For each concentration
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determination experiment, a sigmoid curve fit for the standard
antibody was obtained using equation 1 in Kaleidagraph. The m1, m2,
and m3 values were collected from the sigmoid fit results. Before
proceeding further, the other antibody data had to be checked for
consistency. To do so, sigmoid fits were obtained for each of the other
sets of antibody data. The antibody concentrations from the standard
antibody were substituted for these curves since their concentrations
were still unknown at this stage. The purpose of these sigmoid fits
was to make sure the magnitudes of all the curves are comparable to
the standard curve. Therefore, the only the relevant value from these
curves is the magnitude, m3. Generally, they are very close within the
same experiment. If they are not, then aberrant curves should be
scaled to have the same magnitude as the standard curve. This
simply requires multiplying each y value of the unknown by the ratio
of the standard curve magnitude to the aberrant curve magnitude. If
this scaling is not performed, the calculated concentration will be
wrong.

To calculate the concentration of an unknown, a y value was
selected from the middle linear segment of the sigmoid curve data. y
values as near the midpoint of the curve as possible were selected
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(Figure 10, red lines). The y value along with the initial antibody
dilution factor, the dilution factor at the selected data point, and the
sigmoid fit data from Kaleidagraph were all entered into equation 2.
This equation yields the concentration of the unknown antibody. The
calculation was repeated with multiple y values from the linear
segment.

This served to verify the concentration results and obtain

greater accuracy.
Concentration = d*2^w*10^(-m2*ln((m3-y)/y)+m1) Equation 2.
The reported concentration is molar (M). d is the initial dilution
factor of the unknown antibody, 100 in this protocol. w is the
well number in the middle linear segment of the sigmoid curve
selected for concentration determination. It is not the number
from the ELISA plate, but rather the number of the dilution step
in the series. For example, w would be 9 for well A2 in figure 9.
y is the activity, y value measured in fmoles of Europium, in the
selected well. ln is natural log. m1, m2, and m3 are the values
obtained from the sigmoid fit to equation 1in Kaleidagraph.

Antibody Fragmentation
Reduced IgM (rIgM) fragments of WO2 were generated for use in
antibody fragment binding assays. The rIgM fragment is similar to a
reduced IgG in that it consists of one heavy and one light chain only
(Figure 5). It is a monovalent fragment of the IgM molecule. That is,
it possesses only one binding domain. A reduction and alkylation
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protocol was used to separate the fragments at disulfide bonds and
subsequently alkylate the cysteines preventing reassociation (Pierce).

Before fragmentation, the WO2 sample was purified with an IgM
purification column, HiTrap IgM Purification HP (Amersham Pharmacia
Biotech), using the provided protocol. The following reduction and
alkylation protocol was adapted from the Immunopure IgM
Fragmentation Kit (Pierce). 500 µL of a 1 to 2 mg/mL WO2 sample
was transferred into a 1.5 mL microcentrifuge tube along with 36 µL of
42 mg/mL 2-mercaptoethanolamine, and 500 µL of 50 mM Tris pH 8.0.
The final concentration of 2-mercaptoethanolamine should be 1.5
mg/mL. This concentration is intended to reduce the WO2 to rIgM
fragments without further reduction to separate heavy and light
chains. The reaction was incubated for 30 minutes in a 37°C water
bath. At the end of this time, 65 µL of 123 mg/mL iodoacetic acid was
added to a final concentration of 8 mg/mL. The reaction was
incubated for 15 minutes at room temperature in the dark. Iodoacetic
acid alkylates sulfhydryl groups on cysteines, preventing them from
reforming disulfide bonds. When this reaction was complete, the
sample was injected into a 3 mL capacity dialysis cassette of 3 kDa
MW cutoff (Pierce).

It was dialyzed overnight at 4°C against 1xPBS
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with 0.02% sodium azide added as a preservative. Fragmentation was
verified by running a nonreducing PAGE gel of the sample.

Section 2. Phage Display
The pComb3X Phagemid Vector
The pComb3X phage display vector was used for the phage
display work described herein. It was obtained from the Barbas
laboratory [42]. This vector is approximately 3.4kb in length,
excluding the SfiI-flanked Fab DNA segment. This segment is
approximately 1.5kb in length [42]. This vector has numerous
properties desirable for phage display experiments [42]. A breakdown
of the characteristics of this vector is shown in figure 11. The vector
imparts ampicillin / carbenicillin resistance to E. coli cells possessing it.
This allows for simple selection of infected cells. The gene encoding
the fusion protein in the plasmid possesses a few important additions.
The ompA and pelB signal peptides direct the secretion of the light and
heavy chains, respectively, into the bacterial periplasm. This becomes
useful when expression of soluble Fab protein is desired. There is a
hexahistidine tag (H6) useful for nickel-affinity purification of the Fab
protein. There is a hemagglutinin (HA) tag which allows for detection
of the Fab using anti-HA antibodies. There is an amber codon useful
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Figure 11. The pComb3X phagemid display vector. This vector is
approximately 3.4kb in length, excluding the SfiI-flanked Fab DNA
segment [42]. This segment is approximately 1.5kb in length. The
diagram shows the region immediately flanking the antibody genes.
lacZ is the promoter. Shine-Dalgarno (SD) sequences, which help to
bring the mRNA initiation codon to the ribosome, precede each gene.
SfiI, SacI, XbaI, XhoI, SpeI, and NheI are restriction sites. ompA and
pelB are leader sequences that encode signal peptides directing
protein secretion into the periplasm. VL and CL are the variable and
constant domains of the antibody light chain, respectively. VH and CH1
are the variable and constant domains of the antibody heavy chain,
respectively. H6 is a hexahistidine tag. HA is a hemagglutinin tag.
The amber codon is a stop codon that is suppressed in certain cell
strains. trp is the transcription terminator. (Adapted from Barbas,
C.F., 3rd, et al., Phage Display: A Laboratory Manual. 2002.)
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for controlling expression of the fusion protein. This codon allows for
this control because of the way different bacterial strains interpret it.
In suppressor strains, this codon is interpreted as an amino acid and
results in expression of the full-length fusion of the Fab heavy chain
and phage gp3 fragments. In nonsuppressor strains, it is interpreted
as a stop codon. This results in expression of the heavy chain without
the phage gp3 fragment (Figure 11). Both the heavy and light chains
are exported to the periplasm. The oxidizing environment there
facilitates the association of the two chains via disulfide bonding
(Figure 11). This allows for soluble expression of Fab protein.

PCR Random Mutagenesis
The goal of the phage display experiments was to generate a
library of antibody fragments and select for those with amyloid-binding
properties. PCR random mutagenesis was used to generate the
starting library. Before beginning this procedure, a stock of the
starting phagemid clone was prepared since only a very small amount
was available. The starting clone was pComb3XTT provided by the
Barbas laboratory [42]. Electrocompetent E. coli cells (XL1-Blue,
Stratagene) were transformed with the pComb3XTT vector. Before
transformation, the received pComb3XTT vector preparation and an
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electroporation cuvette (Gene Pulser Cuvette, BIO-RAD) was placed on
ice for 10 minutes. Just before transformation, a tube of 100 µL of
XL1-Blue cells was thawed on ice. 0.5 µL of the received pComb3XTT
vector preparation was added to the tube of thawed cells and mixed by
pipeting up and down. The tube was incubated on ice for 1 minute. A
200 µL pipet tip with the end snipped off was used to transfer the cells
to the electroporation cuvette. The cuvette was transferred to a BIORAD Gene Pulser and electroporation was carried out at 2.5 kV, 25 µF,
and 200 Ω. A time constant of 4.0 to 4.5 is expected. Anything
outside this range indicates likely failed electroporation, possibly due
to presence of too much salt. The cuvette was flushed immediately
after electroporation with 1 mL followed by 2 flushes with 2 mL of
room temperature SOC medium. These flushes were combined into a
50 mL polypropylene tube. This culture was shaken at 225 rpm for 1
hour at 37°C in a New Brunswick Scientific C25 Incubator Shaker.

10 mL of SB medium, 3 µL of 100 mg/mL carbenicillin, and 30
uL of 5 mg/mL tetracycline was added to the culture. Carbenicillin
selects for cells carrying the phagemid. The 15 mL culture was shaken
at 225 rpm for 1 hour at 37°C. 4.5 µL of 100 mg/mL carbenicillin was
added and the culture was shaken for another hour. The culture was
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transferred to a 1 L Erlenmeyer flask. 185 mL of prewarmed (37°C)
SB medium, 92.5 µL of 100 mg/mL carbenicillin, and 370 µL of 5
mg/mL tetracycline was added. The 200 mL culture was shaken
overnight at 225 rpm and 37°C. The next day, the culture was split
into 5 roughly 40 mL lots in 50 mL polypropylene tubes. Glycerol
stocks were prepared from all but 1 tube by adding glycerol to
approximately 15% in each tube. That is about 7 mL of glycerol added
to each tube and mixed thoroughly by pipeting up and down. These
glycerol stocks were stored at -80°C. With an ample supply of
pComb3XTT infected cells in storage, the remaining tube was used for
a phagemid DNA preparation following the maxiprep (Qiagen)
protocol. The pComb3XTT phagemid preparation was used in PCR
random mutagenesis [43].

The pComb3XTT clone encodes a human Fab antibody specific to
tetanus toxoid, an approximately 150 kDa MW bacterial protein [43].
The Fab fragment of an IgG (Figure 5a) possesses the light chain
variable (VL) and constant (CL) domains. It also possesses the heavy
chain variable domain (VH) and constant domain 1 (CH1). Since the
goal was to get anti-amyloid antibodies, the heavy and light chain
genes were mutagenized to generate a library of mutants. PCR
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primers were designed for amplifying the Fab DNA. The sense primer,
PC3SENSE, is just before VL and the reverse primer, PC3REVERSE, is
just after CH1 (Figure 11, Table 2). Error-prone PCR was used to
generate mutated Fab DNA from the phagemid clone. This technique
involves the addition of manganese to the reaction. This causes dNTP
missubstitutions. Several sets of conditions based on a published
protocol [44] were tested before useable yields could be obtained.

The following reaction mix provided the best yields: 100 pmol
sense primer, 100 pmol reverse primer, 10 µL 10xPCR buffer
(Promega), 28 µL MgCl2 (7 mM final from 25 mM stock), 0.2 mM dATP,
0.2 mM dGTP, 1 mM dCTP, 1 mM dTTP, 0.25 mM MnCl2 (200 mM
stock, autoclaved), 5 Units Taq (Promega), volume to 100 µL with
nuclease-free water (Promega). The following cycling conditions were
used: 5 minute preheat at 95°C, 50 cycles of 15 seconds at 94°C, 30
seconds at 45°C, and 90 seconds at 72°C. Normally, 20 to 30 cycles
are executed, but 50 cycles were used to increase yields. The 5
minute preheating step was used to ensure that the DNA strands were
fully melted.
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Table 2. PCR primers. PC3SENSE and PC3REVERSE were used for
amplifying the Fab DNA, including both heavy and light chain
sequences, from the pComb3X vector. They were also used in the
mutagenic PCR of this DNA sequence. OMPSEQ and PELSEQ were
used for sequencing reactions of the light and heavy chain sequences,
respectively.
Primer
Name

Length

Sequence (5’ -> 3’)

41

GAGGAGGAGGAGGAGGAGTGGCACTGGCT
GGTTTCGCTACC

PC3REVERSE

39

GAGGAGGAGGAGGAGGAGAGAAGCGTAGT
CCGGAACGTC

OMPSEQ

22

AAGACAGCTATCGCGATTGCAG

PELSEQ

21

ACCTATTGCCTACGGCAGCCG

PC3SENSE
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The mutagenic PCR products were gel purified via the PCR
purification protocol (Qiagen). Both the purified pComb3X phagemid
vector and purified mutagenic PCR products were digested with the
restriction endonuclease, SfiI (Roche). Digestion was carried out by
combining approximately 20 µg of the phagemid or 10 µg of the
mutagenic PCR products with 360 Units of SfiI and 20 µL of 10x buffer
M. DNA concentrations were calculated by taking absorbance readings
at 260 nm using a Molecular Devices Spectramax Plus spectrometer.
For each sample, a blank reading was first taken by filling a quartz
cuvette with deionized water. The cuvette was emptied and the DNA
sample was diluted 1:50 into deionized water and transferred into the
same quartz cuvette to be read. The concentration was calculated
using equation 3. The total amount of DNA in a given sample was
calculated by multiplying this concentration by the total volume of the
sample. The digestion reaction volumes were adjusted to 200 µL with
nuclease-free water and the reaction was incubated for 5 hours at
50°C. The mutagenic PCR products and the phagemid vector with the
Fab insert cut out were gel purified using the spin miniprep protocol.
DNA concentration = A260 * d * 50 µg/mL Equation 3.
A260 is the absorbance reading of the sample at 260 nm. d is the
dilution factor of the DNA sample into deionized water, 50 as
described above. 50 µg/mL is a constant used to relate the
absorbance at 260 nm to the amount of DNA in the sample.
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The purified products were ligated with T4 DNA ligase (Roche) to
generate a phagemid library. Ligation was carried out by combining
approximately 1.4 µg of cut pComb3X, 1.4 µg of cut mutagenic PCR
products, 40 µL of 5x ligase buffer (Roche), and 10 µL of T4 DNA
ligase. The reaction volume was adjusted to 200 µL with nuclease-free
water and the reaction was incubated overnight at room temperature.
Successful ligation was verified by running the ligation reaction
products on a 1% agarose gel alongside the cut products and the
uncut phagemid. This library was ethanol precipitated and washed for
concentration, purification, and storage. At a later stage in the work,
6 clones were selected to be sent off for sequencing to verify
successful mutagenesis. The OMPSEQ primer was used for these
sequencing reactions (Table 2). The resulting electropherograms were
examined for errors over 350 bases from each clone. The number of
mutations relative to the unmutated clone were counted and divided
into the total number of bases counted to get the mutation rate.
Roughly a 1.5% rate of base mutation was found. Furthermore,
BLAST searches on these sequences verified them to be human
antibody κ light chain.
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Amplification of Helper Phage
Before undertaking the phage display experiments, helper phage
needed to be prepared. These must be ordered in a small amount and
amplified significantly to provide enough for the phage display
experiments. VCSM13 helper phage (Stratagene), derived from the
M13 K07 mutant, were ordered and amplified to an appropriate titer
for use in the phage display experiments by using the protocol adapted
from [42].

To being the procedure, 2 mL of SB medium was inoculated with
2 µL of E. coli cells (XL1-Blue, Stratagene). 4 µL of 5 mg/mL
tetracycline was added and the culture was shaken at 225 rpm for 1
hour at 37°C. Tetracycline selects for F+ male E. coli cells. During the
incubation, 3 dilutions of the ordered VCSM13 helper phage were
made up in SB medium: 10-6, 10-7, and 10-8. 1 µL of each dilution was
added to a separate 50 µL lot of this culture and incubated at room
temperature for 15 minutes. In the mean time, 3 LB+tetracycline
agar plates were prewarmed to 37°C. The 3 lots of infected cells were
each diluted into 1 mL of SB medium and plated on a separate
LB+tetracycline agar plate. These plates were incubated overnight at
37°C. Sometimes the lowest dilution plate may have no colonies or
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the highest dilution plate may have a lawn from which individual
colonies cannot be picked. This is the reason 3 phage dilutions are
used. It ensures there is at least one plate from which isolated
VCSM13 phage plaques can be picked.

The next day, 10 mL of prewarmed (37°C) SB medium was
inoculated with 10 µL of XL1-Blue cells. 20 µL of 5 mg/mL tetracycline
was added and the culture was shaken at 225 rpm for 1 hour at 37°C.
A single VCSM13 plaque was transferred from one of the plates to the
culture using a sterile pipet tip. The culture was shaken at 225 rpm
for 2 hours at 37°C. It was transferred into to a 1 L Erlenmeyer flask
with 240 mL of prewarmed (37°C) SB medium. 500 µL of 5 mg/mL
tetracycline and 350 µL of 50 mg/mL kanamycin was added.
Kanamycin selects for cells infected with VCSM13 phage since this
phage genome imparts kanamycin resistance. The 250 mL culture was
shaken overnight at 225 rpm and 37°C.

The next day, the culture was split into 6 50 mL polypropylene
tubes and spun at 2,500g for 15 minutes using the Beckman Avanti J25I centrifuge and the JA-20 rotor. The supernatants were transferred
to fresh 50 mL tubes and incubated in a water bath at 70°C for 20
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minutes. They were spun again at 2,500g for 15 minutes in the same
centrifuge and rotor. The supernatants were transferred to fresh 50
mL tubes and stored at 4°C until needed.

After the VCSM13 helper phage preparation was completed, the
phage titer was determined. The protocol adapted from [42] was used
to check for a sufficient phage titer. 2 mL of SB medium was
inoculated with 2 µL of XL1-Blue cells. 4 µL of 5 mg/mL tetracycline
was added and the culture was shaken at 225 rpm for 1 hour at 37°C.
During the incubation, 3 dilutions of the VCSM13 helper phage
preparation were made up in SB medium: 10-7, 10-8, and 10-9. 1 µL of
each phage dilution was added to a separate 50 µL lot of this culture
and incubated at room temperature for 15 minutes. The infected cells
were diluted into 1 mL of SB medium and plated onto 3 separate
LB+tetracycline agar plates. These were incubated overnight at 37°C.

The next day, the number of plaques on each plate was counted.
The 10-7 plate may have an uncountable lawn or the 10-9 plate may
have few or no colonies. At least 1 or 2 plates should have an
adequate number of colonies to count. The phage titer was
determined by entering the count and the phage dilution factor for
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each plate into equation 4. The titer should be approximately 1012 to
1013 (plaque-forming units/mL) pfu/mL. The titer slowly decreases
over time, but the VCSM13 phage preparation is stable for months at
4°C.
Phage input titer = (n * d * 50 µL) / 1 µL Equation 4.
n is the number of colonies counted on the plate. d is the
dilution factor of the phage preparation: 107, 108, or 109. 50 µL
is the volume of the cell culture infected. 1 µL is the volume of
the phage preparation dilution used for infection. The units are
pfu/mL [42].

Phage Selection
The first round of phage selection, also called panning, began
with library ligation and transformation. The protocol for this process
was adapted from [42]. To begin with, 1.4 µg of SfiI-cut pComb3X
was combined with 650 ng of SfiI-cut mutagenic PCR product into a
1.5 mL microcentrifuge tube. 10 µL of T4 DNA ligase (Invitrogen) and
40 µL of 5x ligase buffer was added and the sample volume was
adjusted to 200 µL with nuclease-free water. This ligation reaction
was incubated overnight at room temperature to allow for complete
ligation. Successful ligation was verified by running the ligation
reaction products on a 1% agarose gel.
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The ligation products were precipitated by adding 1 µL of
glycogen, 20 µL (0.1 volumes) of 3 M sodium acetate pH 5.2, and 440
µL (2.2 volumes) of ethanol. The reaction was mixed by inverting the
tube several times. The reaction was incubated overnight at 4°C. The
ligation products were spun down in a tabletop microcentrifuge
(Eppendorf Centrifuge 5417R) at 20,000 rpm and 4°C for 15 minutes.
The supernatant was discarded and the pellet was washed twice with
70% ethanol. The tube containing the pellet was drained, tapped dry
onto a paper towel, and left to sit for 15 minutes in a fume hood to
evaporate the remaining ethanol. The dried pellet was dissolved in 30
µL of nuclease-free water by heating to 37°C and vortexing to assist
dissolution. This is the ligated library sample. It is imperative that
this sample is well washed and well dried. Remaining salt or ethanol
could interfere with transformation.

Before transformation, the ligated library sample and 2
electroporation cuvettes were placed on ice for 10 minutes. Just
before transformation, a tube of 100 µL of XL1-Blue cells was thawed
slowly on ice. Though 2 transformations were ultimately done, only
one tube of cells was thawed at a time. This was done to prevent
thawed cells sitting too long before transformation. The longer they
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sit, the lower the transformation efficiency. Only after completely
finishing the first transformation process, was the second tube of cells
thawed.

7 µL of the ligated library sample was added to the tube of
thawed E. coli cells and mixed by pipeting up and down. The
remaining ligated library sample was stored at -80°C after completing
both transformations. The cells were incubated on ice for 1 minute
after adding the library sample. A 200 µL pipet tip with the end
snipped off was used to transfer the cells to the electroporation
cuvette. The cuvette was transferred to the BIO-RAD Gene Pulser and
electroporation was carried out at 2.5 kV, 25 µF, and 200 Ω. A time
constant of 4.0 to 4.5 is expected. The cuvette was flushed
immediately after electroporation with 1 mL followed by 2 flushes with
2 mL of room temperature SOC medium. These flushes were
combined into a 50 mL polypropylene tube. This culture was shaken
at 225 rpm for 1 hour at 37°C.

10 mL of SB medium, 3 µL of 100 mg/mL carbenicillin, and 30
uL of 5 mg/mL tetracycline was added to the culture. 2 µL was
removed from the culture and diluted into 200 µL of SB medium. Onto
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2 separate LB agar+carbenicillin plates, 10 µL and 100 µL of this
1:100 dilution was plated and the plates were incubated overnight at
37°C. These plates were used for determining phage titer (Equation
5). The next day, the number of colonies on each plate was counted.
The phage titer was determined by entering the counts, the plating
volumes, 10 µL or 100 µL, and the culture volumes, 15 mL, into
equation 5. The 15 mL culture was shaken at 225 rpm for 1 hour at
37°C. 4.5 µL of 100 mg/mL carbenicillin was added and the culture
was shaken for another hour.
Phage output titer = (n * 100 * Vc) / p Equation 5.
n is the number of colonies counted on the plate. 100 is the
dilution factor of the infected culture: 200 µL / 2 µL. Vc is the
volume of the cell culture infected: 15 mL or 8 mL. p is the
plating volume: 0.01 mL or 0.1 mL. The units are plaqueforming units/mL or pfu/mL [42].
The culture was transferred to a 1 L Erlenmeyer flask and 2 mL
of VCSM13 helper phage was added. 183 mL of prewarmed (37°C) SB
medium, 92.5 µL of 100 mg/mL carbenicillin, and 370 µL of 5 mg/mL
tetracycline were added. The 200 mL culture was shaken at 225 rpm
for 2 hours at 37°C. 280 µL of 50 mg/mL kanamycin was added and
the culture was shaken overnight at 225 rpm and 37°C. Kanamycin
selects for helper phage infected cells. This prevents the faster-
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growing uninfected cells from out-competing and overtaking the
phage-producing infected cells.

The 200 mL culture was transferred to a 500 mL polypropylene
centrifuge bottle and spun at 3,000g for 15 minutes at 4°C using the
Beckman Avanti J-25I centrifuge and the JLA-10.5 rotor. The resulting
supernatant was transferred to a clean 500 mL centrifuge bottle and
32 mL of 25% PEG-8000 / 15% NaCl was added. This was pipeted up
and down to mix and kept on ice for 30 minutes. During this waiting
period, the cell pellet was resuspended in 1 mL of SB medium,
transferred to a 2 mL microcentrifuge tube, and stored at -80°C. The
pellet can later be used in a phagemid DNA preparation. The
supernatant with 25% PEG-8000 / 15% NaCl added was spun at
15,000g in the same centrifuge and rotor as earlier for 15 minutes at
4°C. The pellet is the phage pellet. The supernatant was discarded
and the bottle was drained by sitting it lip-down on paper towels for 10
minutes. The bottle was gently tapped to the paper towels to remove
the last few drops and the lid was wiped dry.

The phage pellet was thoroughly resuspended in 2 mL of 1%
BSA in 1xPBS. This suspension was transferred to a 2 mL
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microcentrifuge tube and spun in a tabletop microcentrifuge at 20,000
rpm and 4°C for 5 minutes. The resulting clarified supernatant was
transferred to a clean 2 mL microcentrifuge tube. The pellet,
consisting mainly of cell debris, was discarded. Sodium azide was
added to the preparation to 0.02% as a preservative so the
supernatant could be stored at 4°C. This preparation is the phage
library, which was used immediately (the same day) for panning. It
can be stored and used at a later date, but it must be reamplified
before panning. This is necessary, because the activity of the
presented Fab may drop over time in storage since it is not as rugged
as the rest of the phage particle.

Immediately after library ligation and transformation was
completed, the first round of panning was started. This process was
employed for 3 rounds, though more rounds could be used if needed.
The protocol was adapted from [42]. To begin with, 2 wells of a 96well high-binding polystyrene ELISA plate with flat-bottom wells
(Corning/Costar) were coated with 200 ng of Aβ amyloid fibrils
suspended in 50 µL of 1xPBS. The plate was incubated overnight at
37°C uncovered. The coated wells were rinsed 2 times with ELISA
wash buffer. 250 µL of 3% BSA was added to each well. The plate
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was covered with a plate sealer (Costar) and incubated for 1 hour at
37°C. During the incubation, a starter culture was prepared. 2 mL of
SB medium and 4 µL of 5 mg/mL tetracycline was added to a 15 mL
polypropylene tube and inoculated with 2 µL of XL1-Blue cells. An
identical culture was prepared and both were shaken at 225 rpm for 2
to 2.5 hours at 37°C. The OD of each should reach about 1. This
culture was used at a later stage in the protocol.

The blocking solution was shaken out of the plate and 50 µL of
the phage library preparation was added to both wells. The plate was
sealed and incubated for 1 hour at 37°C. The phage solution was
shaken out of the plate and both wells were washed 5 times each with
ELISA wash buffer in the first round of panning. In the second and
third rounds of panning, they were washed 10 times each. The
thorough washing should remove most of the unbound phage from the
wells. The remaining wash buffer was shaken out and 50 µL of freshly
prepared 10 mg/mL trypsin (Sigma) in 1xPBS was added to each well.
There is a trypsin-sensitive flexible linker between the heavy chain and
gp3 fragment in the pComb3X construct. This allows trypsin to cleave
bound phage particles from the plate, freeing them into solution [42].
The plate was sealed and incubated for 30 minutes at 37°C. The
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contents of each well were pipeted up and down 10 times to
thoroughly resuspend cleaved phage particles. The contents of both
wells were transferred to one of the 2 mL cultures prepared earlier.
The infected culture was incubated at room temperature for 15
minutes.

6 mL of prewarmed (37°C) SB medium, 1.6 µL of 100 mg/mL
carbenicillin, and 12 µL of 5 mg/mL tetracycline were added to a 50
mL polypropylene tube. The phage-infected 2 mL culture was
transferred to this tube. 2 µL was taken from this culture and diluted
into 200 µL of SB medium. Onto 2 separate LB agar+carbenicillin
plates, 10 µL and 100 µL of this 1:100 dilution was plated and
incubated overnight at 37°C. These plates were used for determining
phage output titer (Equation 5). The 8 mL culture was shaken at 225
rpm for 1 hour at 37°C. 2.4 µL of 100 mg/mL carbenicillin was added
and the culture was shaken for another hour. In the mean time, 10-8
and 10-9 dilutions of the phage preparation were prepared in 1% BSA
in 1xPBS. 50 µL lots of XL1-Blue cells were infected with 1 µL of each
phage dilution. These were incubated at room temperature for 15
minutes. Onto 2 separate LB agar+carbenicillin plates, each lot of
infected cells was plated. These plates were used for determining
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phage input titer (Equation 4). All 4 plates, input and output titer,
were incubated overnight at 37°C. The next day, the number of
colonies on each plate was counted. The input titers were determined
by entering the counts and phage dilution factors into equation 4. The
output titers were determined by entering the counts, the plating
volumes, and the culture volumes, 8 mL, into equation 5.

The 8 mL culture was transferred to a 1 L Erlenmeyer flask along
with 2 mL of VCSM13 helper phage. 90 mL of prewarmed (37°C) SB
medium, 46 µL of 100 mg/mL carbenicillin, and 184 µL of 5 mg/mL
tetracycline was added. The 100 mL culture was shaken at 225 rpm
for 2 hours at 37°C. 140 µL of 50 mg/mL kanamycin was added and
the culture was shaken overnight at 225 rpm and 37°C. An ELISA
plate was coated as described earlier and incubated overnight. This
plate is for use in the next round of panning, so it was not prepared
during the final round of panning.

The 100 mL culture was transferred to a 500 mL polypropylene
centrifuge bottle and spun at 3,000g for 15 minutes at 4°C using the
Beckman Avanti J-25I centrifuge and the JLA-10.5 rotor. The
supernatant was transferred to a clean 500 mL centrifuge bottle and
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16 mL of 25% PEG-8000 / 15% NaCl was added. This was pipeted up
and down to mix and kept on ice for 30 minutes. In the mean time,
the cell pellet was resuspended in 1 mL of SB medium, transferred to a
2 mL microcentrifuge tube, and stored at -80°C. Also, the ELISA plate
wells coated overnight were washed and blocked as described earlier.
The supernatant with 25% PEG-8000 / 15% NaCl added was spun at
15,000g in the same centrifuge and rotor for 15 minutes at 4°C. The
pellet is the phage pellet. The supernatant was discarded and the
bottle was drained by sitting it lip-down on paper towels for 10
minutes. The bottle was gently tapped to the paper towels to remove
the last few drops and the lid was wiped dry.

The phage pellet was thoroughly resuspended in 2 mL of 1%
BSA in 1xPBS. This suspension was transferred to a 2 mL
microcentrifuge tube and spun in a tabletop microcentrifuge at 20,000
rpm and 4°C for 5 minutes. The resulting clarified supernatant was
transferred to a clean 2 mL microcentrifuge tube. The pellet,
consisting mainly of cell debris, was discarded. Sodium azide was
added to the preparation to 0.02% as a preservative so the
supernatant could be stored at 4°C. This preparation is the phage
library, which was used immediately for the next round of panning.
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That is, the protocol was started over from the beginning right away,
except on the last round of panning.

Phage ELISA
During the panning process, the progression was monitored to
ensure that the library was being enriched in amyloid-binding phage.
Phage ELISA experiments were run on the phage libraries at each step
to test the affinity of the library at a given stage for amyloid. The
phage ELISA protocol shares some similarities to the ELISA protocol
already described except for a few key differences. In place of a
primary antibody, a phage library was used. For a secondary
antibody, an anti-M13 phage antibody was used. Therefore, this
protocol tests the ability of the library as a whole to bind amyloid
fibrils. It was also used to test individual clones.

For each phage ELISA, columns 1 and 2 of a 96-well highbinding polystyrene ELISA plate with flat-bottom wells were coated
with 200 ng of Aβ amyloid fibrils suspended in 50 µL of 1xPBS. The
plate was incubated overnight at 37°C uncovered. The next day, the
plate was washed 2 times with ELISA wash buffer. To block the plate,
each well was filled with 250 µL of ELISA blocking solution. The plate
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was covered with a plate sealer and incubated at 37°C for 1 hour. 100
µL of ELISA blocking solution was pipeted into each well of columns 1
and 2. 100 µL of the fresh phage preparation was transferred into well
A1, making 200 µL in total in the well, and pipeted up and down 4
times to mix (Figure 9). This process was continued down column 1,
from well H1 to well A2, and down thru well F2. The plate was
covered with a plate sealer and incubated at 37°C for 1 hour. The last
2 wells are for taking background readings since they contain no
phage.

The plates were washed 2 times with ELISA wash buffer. A
1:5000 dilution of the secondary antibody, biotinylated anti-M13 phage
(Exalpha), was prepared in ELISA blocking solution. 100 µL of this
preparation was pipeted into each well. The plate was covered with a
plate sealer and incubated at 37°C for 40 minutes. The plate was
washed 2 times with ELISA wash buffer. A 1:1000 dilution of Delfia
Europium-labeling streptavidin (Perkin Elmer) was prepared in ELISA
blocking solution. 100 µL was pipeted into each well. The plate was
covered with a plate sealer and incubated at room temperature in the
dark for 1 hour. The plate was washed 3 times with ELISA wash
buffer. 100 µL of Delfia enhancement solution (Perkin Elmer) was
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pipeted into each well and a Wallac Victor2 1420 Multilabel Counter
was used for detection. The binding data were analyzed much the
same as in the other ELISA experiments. However, no concentration
values were available. Binding results were plotted against log(dilution
factor of phage) and the curves were examined qualitatively. No
calculations were done based on these data.

After the panning process was completed and the library was
enriched in fibril-binding phage, clones were selected for further
analysis. The protocol for picking clones begins with preparing a
starter culture. 2 mL of SB medium and 4 µL of 5 mg/mL tetracycline
were added to a 15 mL polypropylene tube and inoculated with 2 µL of
XL1-Blue cells. An identical culture was prepared for each round of
panning conducted and for the nonpanned library (4 cultures total for
3 rounds of panning and the nonpanned library). These cultures were
shaken at 225 rpm for 2 to 2.5 hours at 37°C. The OD of each should
reach about 1. 50 µL of each phage preparation, one from each round
of panning, was added to a separate culture and incubated at room
temperature for 15 minutes. Onto LB agar+carbenicillin plates, 10 µL
of each culture was plated. These plates were incubated overnight at
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37°C. Less or more culture may be plated if 10 µL results in too many
or too few colonies.

The next day, 2 mL of SB medium, 4 µL of 5 mg/mL tetracycline,
and 1 µL of 100 mg/mL carbenicillin were added to several 15 mL
polypropylene tubes. Enough tubes were prepared for the desired
number of clones. Isolated colonies were picked from each plate with
sterile pipet tips and cultures were inoculated with a single clone into
each tube. 8 clones were picked on the first run of this protocol and
16 on the next. The cultures were shaken at 225 rpm for 2 to 2.5
hours at 37°C. The plates were stored by sealing with parafilm and
keeping at 4°C. 6 mL of prewarmed (37°C) SB medium, 3 µL of 100
mg/mL carbenicillin, and 12 µL of 5 mg/mL tetracycline was added to
a 50 mL polypropylene tube for each clone. The phage-infected 2 mL
cultures were added to these tubes. The 8 mL cultures were shaken
overnight at 225 rpm and 37°C. The following day, glycerol stocks
were prepared from these cultures by adding glycerol to approximately
15% in each culture tube. That is about 1 to 1.2 mL of glycerol per
tube. These glycerol stocks were mixed thoroughly by pipeting up and
down and stored at -80°C.
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After selecting clones, the affinity of each was tested to
determine if it possessed the desired binding properties. This entailed
producing small-scale phage preparations of the clones and testing
their binding properties by phage ELISA. The protocol for small scale
phage preparations was adapted from [42]. For each clone to be
tested, 10 mL of SB medium, 20 µL of 5 mg/mL tetracycline, and 5 µL
of 100 mg/mL carbenicillin was added to several 50 mL polypropylene
tubes. Each was inoculated with a glycerol stock scraping from a
different clone. The cultures were shaken at 225 rpm for 6 hours at
37°C. 100 µL of VCSM13 helper phage was added to each culture.
The cultures were shaken for an additional 2 hours at 225 rpm and
37°C. 14 µL of 50 mg/mL kanamycin was added to each culture and
the cultures were shaken overnight at 225 rpm and 37°C.

The next day, 1.2 mL of each supernatant was transferred into a
fresh 2 mL microcentrifuge tube. These tubes were spun at 3,500 rpm
in a tabletop microcentrifuge for 15 minutes. The supernatants were
transferred to fresh 2 mL microcentrifuge tubes and the cell pellets
were frozen since they can later be used in phagemid preparations. To
the 1.2 mL supernatants, 300 µL of 25% PEG-8000 / 15% NaCl was
added. The supernatants with 25% PEG-8000 / 15% NaCl added were
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mixed by inverting the tubes several times. They were incubated on
ice for 30 minutes. The tubes were spun at 20,000 rpm and 4°C for
15 minutes. For each tube, the supernatant was drawn out with a
pipet, taking care not to disturb the pellet. All tubes were spun 20
seconds longer and the remaining supernatant was drawn out. Each
tube was carefully tapped upside down on a paper towel to remove the
last of the PEG. All the tubes were allowed to dry for 10 minutes in a
fume hood. Each phage pellet was resuspended in 100 µL of 1% BSA
in 1xPBS. These clonal phage preparations were used right away in
phage ELISAs as previously described. The only difference was that
100 µL of a clonal phage preparation was used in place of 100 µL of a
phage library preparation. The binding curves were plotted and
examined in the same manner as the phage library ELISA
experiments.

Production of Soluble Fab
Soluble Fab production was explored in selected clones as well
as the original unmutated clone. Each phagemid clone was isolated
and transformed into E.coli cells of a nonsuppressor strain. Cultures
were grown up and induced to produce soluble Fab protein and whole
cell extracts from these cultures were tested for the presence of Fab
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protein. After growing up induced cultures, an acetone extraction
protocol (Dr. Ronald Wetzel) was used to remove lipids and get a total
protein extract. Western blots of the protein extracts were run.

For each clone, a cell pellet prepared earlier was used in a
plasmid preparation to isolate and purify the phagemid DNA. Pellets
saved from the clonal phage ELISA experiments were used. These
were subjected to the spin miniprep protocol (Qiagen).
Electrocompetent E. coli cells of a nonsuppressor strain (TOP10,
Invitrogen) were transformed with each phagemid clone following the
protocol already described under the heading “PCR Random
Mutagenesis”. The only difference was the use of the TOP10 strain of
E. coli in place of the XL1-Blue strain. After electroporation, 10 mL of
SB medium, 3 µL of 100 mg/mL carbenicillin, and 30 uL of 5 mg/mL
tetracycline was added to the 5 mL of SOC medium flushes. The 15
mL culture was shaken at 225 rpm for 1 hour at 37°C. 4.5 µL of 100
mg/mL carbenicillin was added and the culture was shaken overnight
at 225 rpm and 37°C. The next day, glycerol stocks were prepared
from the cultures by adding glycerol to approximately 15% in each
tube and mixing thoroughly by pipeting up and down. These glycerol
stocks were stored at -80°C. The remaining material from the plasmid
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preparation of each clone was sent off for sequencing. Including the
unmutated clone, five clones were sequenced in total. The PELSEQ
and OMPSEQ primers were used for these sequencing reactions (Table
2). BLAST searches on the resulting sequences verified them to be
human antibody heavy chain Fd fragment and κ light chain,
respectively.

For testing soluble Fab production, fresh cultures were prepared
using the glycerol stocks as inoculants. For each clone, 5 mL of SB
medium, and 2.5 µL of 100 mg/mL carbenicillin were added to several
50 mL polypropylene tubes. Since the heavy and light chain genes are
under the lacZ promoter in the pComb3X vector, IPTG can induce their
expression. Each tube was inoculated with a glycerol stock scraping
from a different TOP10 culture clone. The cultures were shaken for 6
hours at 225 rpm and 37°C. 50 µL of 0.1 M IPTG was added to each
culture and the cultures were shaken overnight at 225 rpm and 37°C.

The following day, 1 mL of each culture was transferred to a 2
mL microcentrifuge tube. The tubes were spun at 5,000 rpm in a
tabletop microcentrifuge for 5 minutes. The supernatants were
discarded and the cell pellets were frozen at -80°C. The pellets were
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thawed and each was resuspended in 80 µL of cell suspension buffer.
8 µL of 20% SDS and 8 µL of 1M βME was added. Each cell
suspension was pipeted up and down and vortexed vigorously to mix.
They were heated to 90°C for 2 minutes and then cooled. 1 mL of
acetone was added to each tube and mixed by vortexing. The tubes
were incubated on ice for 10 minutes. They were spun at 5,000 rpm
in a tabletop microcentrifuge for 1 minute. The supernatants were
discarded and the pellets were left in a fume hood for 15 minutes to
dry. The pellets were resuspended in 300 µL of [7.5 parts 1xPBS, 2.25
parts NuPage 4x loading dye (Invitrogen), 0.25 parts 1M βME] by
pipeting up and down and vortexing vigorously. They were heated to
90°C for 2 minutes and then cooled. The tubes were spun at 5,000
rpm in a tabletop microcentrifuge for 1 minute. A protease inhibitor,
Fluka Pefabloc SC (Fisher), was added to 1mM final concentration to
prevent protein degradation. 25 µL of each sample was loaded into a
NuPage polyacrylamide gel lane (Invitrogen) for analysis. The SeeBlue
Plus 2 MW standard (Invitrogen) was loaded into one lane of the gel.
The gel was run through a SDS-PAGE experiment at 150 V for 70
minutes using a BIO-RAD PowerPac 200 following the NuPage protocol
(Invitrogen). 1x MOPS SDS running buffer (Invitrogen) was used in
the run with NuPage antioxidant (Invitrogen) added. Gels prepared in
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this fashion were used in western blot experiments to determine if
there is any Fab protein present.

For each western blot, a western transfer was run onto a PVDF
membrane (BIO-RAD). The NuPage protocol (Invitrogen) was followed
for the transfer. After the transfer, the PVDF membrane was used in a
western blot. The membrane was blocked by incubating in a 5% BSA
solution for 1 hour. The membrane was washed 3 times with ELISA
wash buffer by shaking the membrane in the buffer for 5 minutes each
wash. The membrane was incubated in a 1:2500 dilution of the
primary antibody in ELISA blocking solution for 1 hour. For blots
against the HA tag of the fusion protein, a monoclonal anti-HA biotin
conjugate antibody (Sigma) was used. In another replicate of the
same experiment, a monoclonal anti-HA HRP conjugate antibody
(Roche) was used. For blots against the antibody chains, a polyclonal
goat anti-human IgG, heavy and light chain, HRP conjugate (Pierce)
was used. Since the gel running conditions were reducing, it was
necessary to use chain-specific antibodies rather than anti-Fab
antibodies. A polyclonal mixture was used in case some of the
antibody mutant clones have mutations in the epitope recognized by a
particular monoclonal antibody. In this experiment, a purified human
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IgG was run on the same gel as the positive control. After the primary
antibody incubation, the membrane was washed 3 times as before.
When the primary antibody was a biotin conjugate, ExtrAvidin
Peroxidase (Sigma) was used as a secondary diluted to 1:5000 in
ELISA blocking solution. The membrane was incubated in this solution
for 1 hour. It was washed 3 times as before. After a membrane was
labeled with an HRP conjugate, it was treated with a peroxidase
substrate to stain the labeled bands. A CN/DAB substrate (Pierce) was
used following the provided protocol. The membrane was incubated in
this substrate and monitored until bands developed.
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Chapter III
Antibody Binding Results and Discussion

Several experiments were conducted using the anti-amyloid
antibodies available in our lab. Among these were experiments
studying the binding characteristics of these antibodies to Aβ amyloid
fibrils. These included salt and pH effect experiments to examine antiamyloid antibody binding properties. These also included binding
studies using fragments of these IgM antibodies to determine the
importance of avidity effects to binding. The majority of the work
focused primarily on exploring anti-amyloid antibody binding to
different amyloid fibrils, specifically fibrils of proline and alanine
mutants of Aβ. These experiments sought to explore the impact of
single-residue changes and potential fibril structural differences on
antibody binding.

Salt and pH Effects on WO1 Binding to Aβ Fibrils
This set of experiments was designed to gain some insight into
the nature of WO1 binding to Aβ amyloid. They ask the question of
whether electrostatic or hydrophobic interactions are predominant in
WO1 binding. Electrostatic interactions are sensitive to changes in
buffer ionic strength and pH conditions, whereas hydrophobic
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interactions are not significantly impacted. This is important as a
reliance on electrostatic interactions supports a specific mode of
binding. A dependence on hydrophobic interactions, on the other
hand, more likely suggests nonspecific binding. Binding of the WO1
antibody to Aβ fibrils was tested under various salt and pH conditions
(Table 1). All solutions used in the salt effect experiments were
buffered with 5 mM HEPES. Due to the low ionic strength of this buffer
compound, it should not greatly impact the overall ionic strength of
the buffer. In addition, these solutions were buffered to pH 7.5, near
physiological pH conditions. All solutions used in the pH effect
experiments contained 150 mM NaCl to provide approximate
physiological ionic strength conditions.

Four different salts were tested at comparable ionic strengths to
determine if the particular salt present in the buffer has a significant
impact on antibody binding. The four chosen were 1xPBS, NaCl, KCl,
and NaPO4 (Table 1). 1xPBS is the standard buffer used in the binding
experiments. The other three salts were chosen to compare two
different anions and cations. The affinity varied from about 2 nM in
1xPBS to about 10 nM in 75 mM NaPO4, less than an order of
magnitude difference between the two extremes (Figure 12). Though
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Figure 12. Salt effect on WO1 binding. Binding under various salt
conditions was calculated from sigmoid midpoints: 5 mM HEPES only
was 4 nM, 150 mM NaCl was 4 nM, 150 mM KCl was 8 nM, 75 mM
NaPO4 was 10 nM, 600 mM NaCl was 20 nM, and 1xPBS was 2 nM.
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there was some variation, binding was relatively comparable in the
presence of the different salts.

Binding was tested under three different ionic strength
conditions: 0 mM NaCl, 150 mM NaCl, and 600 mM NaCl (Table 1).
Binding was strongest in the near physiological ionic strength buffer,
150 mM NaCl, at an affinity of 4 nM (Figure 12). In a low ionic
strength buffer, 5 mM HEPES only, binding is similar. In a high ionic
strength buffer, 600 mM NaCl, binding dropped sharply. This
manifested in a reduction of both the magnitude and the affinity of
binding. The significantly reduced binding in high salt suggests that
electrostatic interactions are relatively important to binding and
hydrophobic interactions are relatively unimportant. That is not to say
that binding is solely controlled by electrostatic interactions, but it
does suggest that they are relatively important to binding.

WO1 binding was tested in a range of pH conditions (Table 1).
The data produced a continuum of binding affinities with the strongest
binding at near physiological conditions, pH 7.4 (Figures 13a & b).
There was, however, a discontinuity at pH 5.8 between the PIPES and
citrate buffers (Figure 13b). We are not sure exactly why this
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Figure 13. pH effect on WO1 binding. The curves in graph A show
binding under various pH conditions. Binding affinities were calculated
from the sigmoid midpoints: citrate pH 3.0 showed essentially no
binding, pH 5.8 was 2 nM, PIPES pH 5.8 was more than 20 nM, pH 7.4
was 2 nM, Bicine pH 7.4 was 1.5 nM, pH 8.5 was 16 nM, CHES pH 8.5
was 10 nM, pH 10.0 was very low binding (could not be calculated, but
no better than 50 nM). Graph B is a plot of -log(affinity) across the pH
range of 3.0 to 10.0. Affinities for the pH 3.0 and 10.0 data points
could not be calculated since they were so low. The value 6 was
substituted for each of these.
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inconsistency appeared, but it may be due to buffer effects besides the
pH. Even with the gap present, a clear trend arose with binding
dropping off sharply at higher and lower pH conditions. This indicated
that WO1 is pH-optimized for Aβ amyloid binding. If hydrophobic
interactions were predominant in binding, this would likely not be the
case. This reinforces the salt effect results suggesting that binding
depends at least in part on electrostatic interactions.

Binding of rIgM WO2 Fragments to Aβ Fibrils
This study was conducted to determine if antibody fragments of
lower valency than IgM can still bind Aβ fibrils. Since IgM molecules
possess ten antigen binding domains (Figure 5), there is likely some
avidity effect involved in their binding to amyloid fibrils. That is,
several binding domains contribute to the binding affinity in a
cooperative manner. This study explores the importance of that effect
in the binding of the WO2 IgM molecule to Aβ amyloid. WO2
possesses very similar binding properties to WO1.

The fragment generated was rIgM, a monovalent fragment of the
IgM molecule. The advantage of working with this particular fragment
is that the same secondary antibody, biotinylated goat anti-mouse IgM
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(µ-chain specific), can be used as with the whole IgM molecules in
ELISA experiments. The same binding and concentration
determination experiments were run on these fragments as on the
whole IgM antibodies. The only difference was in calculating
concentrations. The molecular weight of the fragment was treated as
approximately 90 kDa instead of 900 kDa, so the effective
concentration was increased by a factor of ten.

WO2 rIgM binds less strongly to Aβ fibrils than WO2 IgM,
possibly due to the reduction in valency (Figure 14a). However,
control rIgM generated from mouse IgM (Calbiochem) binds more
strongly than control IgM (Figure 14b). In fact, it binds with similar
affinity to WO2 rIgM. This is a surprising result. Perhaps exposure of
constant regions enhances nonspecific binding of the rIgM fragment.
Due to the weaker binding of WO2 rIgM and the stronger binding of
control rIgM, WO2 fragments do not bind significantly more strongly
than control IgM fragments. Avidity effects appear to be important in
WO2 binding to Aβ amyloid fibrils.
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Figure 14. Binding of WO2 rIgM fragments to Aβ fibrils. Graph
A shows that the WO2 rIgM fragment bound much less strongly than
the WO2 IgM: 32 nM versus 2.5 nM. Graph B shows that the control
rIgM fragment bound more strongly than the control IgM: 25 nM
versus 130 nM. The fragments ultimately bound with very similar
affinity: 32 and 25 nM.
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PGA1 Binding to Aβ Amyloid versus Polyglutamine Aggregates
Among the battery of antibodies available in our lab are several
raised against polyglutamine aggregates. In characterizing these, we
found one to be of particular interest because of its ability to bind Aβ
amyloid more strongly than polyglutamine aggregates. This antibody,
PGA1, bound Aβ aggregates much more strongly than it did
polyglutamine aggregates. PGA1 is a monoclonal IgM isolated from
mouse myeloma cultures (Dr. Brian O’Nuallain, unpublished data). It
was generated from a mouse immunized with amyloid-like
polyglutamine aggregates [45]. Approximate PGA1 affinities were: 20
nM to Aβ fibrils, 70 nM to Q30 aggregates, and 70 nM to Q50
aggregates. PGA1 bound to Aβ fibrils at least three times better than
to either polyglutamine aggregate tested (Figure 15). In addition, the
magnitude of the binding affinity at saturation was significantly higher
for Aβ fibrils. These are surprising results considering that PGA1 was
raised against polyglutamine aggregates. The antibody bound
aggregates of entirely different protein constituents more strongly
than the immunogenic aggregates. This highlights the amyloid
structure-specific rather than amino acid sequence-specific nature of
these antibodies.
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PGA1 binding to Aβ fibrils versus polyglutamine aggregates
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Figure 15. PGA1 binding to Aβ fibrils versus polyglutamine
aggregates. Approximate PGA1 affinities: to Aβ fibrils was 20 nM, to
Q30 aggregates was 70 nM, to Q50 aggregates was 70 nM.

89

WO1 and PGA1 Binding to Fibrils of Aβ Proline Mutants
Learning the effects of mutating different residues could tell
more about where and how the anti-amyloid antibodies bind to Aβ
fibrils. Towards this end, WO1 and PGA1 binding to a number of fibrils
of Aβ mutants was analyzed. The first set tested was made up of
proline mutant Aβ fibrils. These were the products of a proline
scanning mutagenesis project [34]. Fibrils of these mutants were
provided by Angela Williams. Though prolines are known to destabilize
β-sheet structure, a defining characteristic of amyloids, fibrils
managed to grow for all the proline mutants tested. However, the
mutant fibrils may be structurally different from wild-type as reflected
in varied fibril stabilities and HD exchange protection [34]. EMs of
these fibrils were obtained and thioflavin T (ThT) binding was
measured to show that the samples are indeed fibrils and not
amorphous aggregates [34]. In addition, HD exchange studies
suggest that the proline mutant fibrils are structurally similar to wildtype Aβ fibrils [34]. Of course, the fibrils are probably not structurally
identical to wild-type. The purpose of these experiments was to
determine if the proline mutant Aβ fibrils are still recognized as
amyloid by the anti-amyloid antibodies. These experiments also
explored differences in binding to each proline mutant fibril.
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WO1 binding to a number of proline mutant fibrils of Aβ was
tested. Binding was tested in triplicate where possible. Due to the
lack of involvement of the amino terminus (~15 residues) in fibril
structure [31-33], many mutants from that region were not tested.
Only a representative few mutants from the amino terminus were
selected. Mutants at residues 18, 19, 20, and 31 were also not tested.
These fibrils were not available at the time of this experiment. A
double proline mutant (23, 30) and a quadruple proline mutant (9, 23,
30, 37) were tested. These both possess proline mutations in each of
the turn regions in the model (Figure 4). The quadruple mutant
possesses two additional mutations, one N-terminal and the other Cterminal of the amyloid core in the model. The affinity of WO1 for
most of the mutant fibrils was comparable to that for wild-type Aβ
fibrils (Figures 16 & 17). In figure 16, the affinity is represented as a
function of the free energy difference approximation (∆∆Gapp) between
WO1 binding to wild-type fibrils and proline mutant fibrils. These
calculations are not entirely legitimate since the binding curve
midpoints on which they are based do not represent true dissociation
constant (Kd) values. However, they are useful approximations for
looking at the data. The affinity was not drastically lower for any of
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Figure 16. Summary of WO1 binding to proline mutants of Aβ.
The six sets of sigmoid curves on the following pages show the binding
affinity obtained for WO1 binding to fibrils of each mutant. These
represent one set of data, but it was obtained in triplicate with a few
exceptions: single replicates for D23P and I32P, duplicates for F4P,
N27P, G29P, 2P and 4P, and 5 replicates for K16P. 2P and 4P are the
double (23, 30) and quadruple (9, 23, 30, 37) proline mutants,
respectively. From the curves, the binding affinity of WO1 for each
mutant fibril was calculated. The free energy difference approximation
(∆∆Gapp) for WO1 binding to each mutant relative to WT fibrils was
calculated using the equation: ∆∆Gapp = R*T*ln(WT affinity / mutant
affinity). R = 1.987 kcal/(°K * mol) and T = 310.14 °K. These values
were plotted on the bar graph with the error bars showing the
standard deviation between replicates. In this figure, a higher,
positive ∆∆Gapp indicates that WO1 binds more strongly to the
particular proline mutant than to WT.
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Figure 17. WO1 binding to proline mutants of Aβ. These graphs
show one set of ELISA binding data for WO1 binding to proline
mutants of Aβ. Kaleidagraph was used to calculate the affinity of WO1
for each mutant by obtaining a sigmoid fit of each curve and extracting
the midpoint. For those curves that did not reach an obvious plateau,
the highest data point was duplicated at x = 6 to approximate a
plateau suitable for a sigmoid curve fit.
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the mutant fibrils, but the affinity for several was significantly higher
than that for wild-type fibrils. In many cases, such as the mutants at
residues 4, 6, 9, and 14, the difference was relatively small with
∆∆Gapp values less than about 0.5 kcal/mol. Several mutant fibrils,
such as those at residues 12, 15, 33, and 37, showed significantly
better binding with ∆∆Gapp values around 0.7 to 1 kcal/mol. One
mutant stood up above all the rest. The K16P mutant fibrils were
bound much more strongly with a ∆∆Gapp value around 1.8 kcal/mol.
This amounts to about twenty times stronger binding compared to
wild-type fibrils. The peak representing this mutant stands out
prominently in figure 16.

Since WO1 managed to bind most of the proline mutant fibrils
comparably or better to wild-type (Figures 16 & 17), it appears that
the structural differences between the different mutant fibrils did not
remove the amyloid characteristics of the fibrils as seen by WO1. Of
particular note, WO1 bound the K16P mutant fibrils of Aβ much more
strongly than wild-type. In our model of Aβ protofilament structure,
residue 16 lies towards the end of a β-sheet (Figure 18a). It is near
the interface between the unstructured amino-terminus and the
amyloidogenic core of the Aβ peptide. The dramatic difference in WO1
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Figure 18. Aβ protofilament cross-section: WO1 and PGA1
binding to mutant fibrils. Based on the binding data, the most
significant residues are highlighted in yellow and pointed out with
arrows. This figure considers proline (P), alanine (A), cysteine (C),
and carboxymethylthio-modified cysteine (CMTC) mutant data. There
are other residues with significant binding enhancement in some
cases, but only the most significant are shown here. Note that
residues 16 and 36 each lie between the amyloid core and the aminoor carboxy-terminus, respectively. Also note that residues 27, 28, 30,
and 31 all flank the second turn within the amyloid core.
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Figure 18. Continued.
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affinity for K16P over all the other single proline mutant fibrils and
wild-type Aβ suggests that this residue is at an important junction to
WO1 binding. There are many possible explanations for why this may
be the case. One possible explanation is that the rigid proline, while
destabilizing fibril structure globally, may serve to solidify a structural
epitope recognized by WO1. Another explanation is that the
destabilization may simply make the antibody epitope more accessible
to WO1. The second explanation could involve “frayed” fibril ends. As
was earlier mentioned, fibrils are composed of multiple protofilaments
wound about one another [23]. It could be the case that fibril
destabilization could weaken the association of these protofilaments at
the fibril ends. These frayed ends could make the WO1 binding site
more accessible. This will be discussed in more detail later.

WO1 binding to double and quadruple proline mutant fibrils was
also tested [31-33]. These results are shown in figures 16 and 17f.
WO1 binding to the double proline (residues 23 and 30) mutant fibrils
was similar to wild-type. WO1 binding to the quadruple proline
(residues 9, 23, 30, and 37) mutant fibrils was surprisingly good. With
four prolines in the sequence, one would have predicted that fibrils
would not grow or would be very unstable. Given that the fibrils did
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grow, one might expect a greatly altered fibril structure. However, the
binding data suggests that the fibrils maintained amyloid character as
seen by WO1. The enhanced affinity of WO1 for these fibrils may be
primarily due to the proline at residue 37 since the single proline
mutants at the other three residues (9, 23, and 30) all seem to have
little impact on binding (Figure 16). In building our model of the
amyloid structure, we have interpreted this result to indicate that
positions 9 and 37 are N-terminal and C-terminal, respectively, to the
β-sheet portion of the amyloid, and positions 23 and 30 are in turn
regions between β-sheet elements (Figure 18). Prolines are more
likely to be tolerated in turn and disordered segments, and at these
positions might thus not be destabilizing to fibril structure.

Since PGA1 possesses strong binding to Aβ amyloid (Figure 15),
its binding was also tested against the array of available proline
mutant Aβ fibrils. PGA1 binding was tested in duplicate. Just as with
WO1, the goal was to see the effects of proline mutations on antibody
binding. Furthermore, this allowed for a comparison of the binding
profiles of WO1 and PGA1 to the proline mutant fibrils. For the most
part, the PGA1 binding profile resembles that of WO1 except for a few
major differences (Figure 19). The enhanced binding for K16P, at
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Figure 19. Summary of PGA1 binding to proline mutants of Aβ.
Data is in duplicate except: 4 replicates for V36P and a single replicate
for G25P. From the binding curves (not shown), the binding affinity of
PGA1 for each mutant fibril was calculated. The free energy difference
approximation (∆∆Gapp) for PGA1 binding to each mutant relative to WT
fibrils was calculated using the equation shown in figure 16. These
values were plotted on the bar graph with the error bars showing the
standard deviation between replicates. In this figure, a higher,
positive ∆∆Gapp indicates that PGA1 binds more strongly to the
particular proline mutant than to WT.
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about 0.8 kcal/mol, is not nearly as pronounced as was found for
WO1. There is an island of enhanced binding from mutants I32P to
V36P. PGA1 binding to V36P was particularly good with a ∆∆Gapp value
around 3.7 kcal/mol. This amounts to about one hundred times
stronger binding compared to wild-type fibrils. This suggests that
residue 36 has a strong influence on the PGA1 binding site, not unlike
the relationship between residue 16 and WO1 binding. In our model,
residue 36 lies towards the end of a β-sheet near the interface
between the unstructured carboxy-terminus and the amyloidogenic
core of the Aβ peptide (Figure 18b). It is within a region of the
peptide reminiscent of the locale of residue 16. Therefore, the
enhanced binding of PGA1 may be due to similar effects as were
discussed for WO1 binding. This suggests that the PGA1 and WO1
binding sites may be related. However, the marked differences in
binding to the proline mutants K16P and V36P emphasizes that the
binding sites are not identical. The other clear difference is the greater
magnitude of binding enhancement to the mutants in the range of
residues 32 to 37 (Figures 16 & 19). Though both WO1 and PGA1 bind
to Aβ fibrils, the different binding patterns they exhibit to proline
mutants suggests they do not target the exact same binding site.
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WO1 and PGA1 Binding to Fibrils of Aβ Alanine Mutants
A project currently in progress involves alanine scanning
mutagenesis of the Aβ peptide sequence. Fibrils of these mutants are
grown up and analyzed with the same techniques used for the proline
mutants (Angela Williams, unpublished data). Alanine mutants should
not have drastically altered fibril structures when compared to proline
mutants. This means the resulting binding data should be more
informative as to local effects of different residues on antibody binding.
Not all of the alanine mutant fibrils were assayed since not all were
available at the time of testing.

Binding was tested in duplicate for all available mutant fibrils.
Like the proline mutant results, WO1 binding to most of the alanine
mutant fibrils was comparable to wild-type. There were, nonetheless,
a few exceptions (Figure 20). The N27A mutant fibrils were bound
much more strongly with a ∆∆Gapp value around 2.1 kcal/mol. This
amounts to about thirty times stronger binding compared to wild-type
fibrils. In the model, this residue lies within a β-sheet (Figure 18a).
Asparagine is a polar amino acid, but it carries no formal charge under
physiological pH conditions. The drastically improved binding to this
alanine mutant is surprising. It is possible that the smaller alanine
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Figure 20. Summary of WO1 binding to alanine mutants of Aβ.
Data is in duplicate except: 3 replicates for K16A and L34A. From the
binding curves (not shown), the binding affinity of WO1 for each
mutant fibril was calculated. The free energy difference approximation
(∆∆Gapp) for WO1 binding to each mutant relative to WT fibrils was
calculated using the equation shown in figure 16. These values were
plotted on the bar graph with the error bars showing the standard
deviation between replicates. In this figure, a higher, positive ∆∆Gapp
indicates that WO1 binds more strongly to the particular alanine
mutant than to WT.
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may be more favorable in this position to the packing of the amyloid
core. This may, in turn, stabilize the epitope recognized by WO1. The
large difference in binding affinity suggests that residue 27 is very
important in WO1 binding to Aβ amyloid.

The K28A mutant fibrils were bound much more strongly with a
∆∆Gapp value around 1.5 kcal/mol. This amounts to about ten times
stronger binding compared to wild-type fibrils. The alanine is
hydrophobic and is much smaller than the positively-charged lysine.
The enhanced binding to these fibrils may stem from a net reduction in
positive charge of the fibrils. The less positive charge may be more
favorable to anti-amyloid antibody binding. However, considering the
results at residue 27, the charge difference may be less important.
Since residue 28 is directly beside residue 27, it may be affected in a
similar manner though to a lesser degree than residue 27. The alanine
may be better suited to packing simply because of the smaller size of
the side group.

The PGA1 binding results followed a similar pattern to the WO1
results (Figure 21). The N27A mutant fibrils were bound even more
strongly with a ∆∆Gapp value around 2.8 kcal/mol. This amounts to
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PGA1 binding to alanine mutants of Abeta
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Figure 21. Summary of PGA1 binding to alanine mutants of Aβ.
Data is in duplicate. From the binding curves (not shown), the binding
affinity of PGA1 for each mutant fibril was calculated. The free energy
difference approximation (∆∆Gapp) for PGA1 binding to each mutant
relative to WT fibrils was calculated using the equation shown in figure
16. These values were plotted on the bar graph with the error bars
showing the standard deviation between replicates. In this figure, a
higher, positive ∆∆Gapp indicates that PGA1 binds more strongly to the
particular alanine mutant than to WT.
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about ninety times stronger binding compared to wild-type fibrils
(Figure 18b). This is three times the ratio demonstrated by WO1. The
K28A mutant fibrils were bound comparably at a ∆∆Gapp value of
around 1.6 kcal/mol. This suggests that residues 27 and 28 carry a
similar importance to both WO1 and PGA1 binding, but residue 27
appears to be even more critical in PGA1 binding.

PGA1 Binding to Cysteine and Modified Cysteine Mutants of Aβ
Among the mutant Aβ amyloid fibrils available in our lab are a
series of single cysteine mutants. In addition to these fibrils are two
sets that have been modified at the cysteine residue. These exploit
the fact that the wild-type Aβ sequence contains no cysteines (Figure
3). One set was modified with the addition of an acetic acid group by
reaction of the cysteine with iodoacetic acid (IAA). These are
carboxymethylthio-modified (CMT) fibrils. The other set was modified
with the addition of a methyl group by reaction of the cysteine with
methyl iodide (MeI). These are methylthio-modified (MT) fibrils. All
three sets of fibrils are products of the work of Dr. Shankaramma
Shivaprasad. The CMT-modification provides a negatively charged
group at the residue while the MT-modification provides a hydrophobic
group. Since these modifications should not alter fibril structure to the
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degree that proline does, testing antibody binding to these fibrils
should be more telling as to the impact of local changes on antibody
binding. These experiments were run to get more insight into the
involvement of individual residues in antibody binding. They act as a
supplement to the alanine mutant data. None of the three sets of
fibrils are complete, so only a few selected mutants were tested (Table
3). PGA1 was the anti-amyloid antibody used in this work.
Accordingly, the cysteine mutant binding results were interpreted in
relation to the other PGA1 binding results.

Binding was tested to all three modified cysteine mutant fibrils at
residue 36 (valine in wild-type) due to its prominence in the proline
mutant data. There did not seem to be much difference in binding to
any of these fibrils or wild-type, suggesting that local changes at this
residue are less important (Table 3). Binding was tested to all three
modified cysteine mutant fibrils at residue 28 and to unmodified
cysteine mutant fibrils at residue 16 because these residues are
lysines in wild-type Aβ (Figure 3). The modified mutant fibrils for
residue 16 were not available. Since lysine is a positively charged
residue at physiological pH, these experiments were intended to
observe the effect of removing or reversing this charge on PGA1
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Table 3. PGA1 binding to cysteine mutant fibrils. This table
shows the affinity of PGA1 for each mutant and for WT fibrils (run on
the same plate on the same day). These data are in single replicates.
From the binding curves (not shown), the binding affinity of PGA1 for
each mutant fibril was calculated. The free energy difference
approximation (∆∆Gapp) for PGA1 binding to each mutant relative to WT
fibrils was calculated using the equation shown in figure 16. These
values are shown in the next to last column. Fibril stability is shown in
the last column. Fibril stability is expressed as a free energy
difference (∆∆G) of fibril formation between the mutant and WT fibrils
[34]. These values were calculated from the critical concentrations,
the molar concentration of soluble peptide present at equilibrium, of
the fibrils [34]. A positive ∆∆G value indicates that the mutant is less
stable than WT. The two most dramatic differences are bold and
highlighted in red.
Binding
Stability
Mutant
WT
∆∆Gapp
∆∆G
Residue Affinity Affinity
(nM)
(nM) (kcal/mol) (kcal/mol)
Cysteine
mutant

CMTmodified
cysteine
mutant
MTmodified
cysteine
mutant

K16C
K28C
I31C
I32C
V36C
K28C
A30C
I31C
M35C
V36C
D23C
K28C
A30C
I31C
V36C

16
3.6
20
25
9.6
22
0.44
3.5
5.6
17
32
8.7
20
18
12

12
20
41
20
12
20
41
41
12
12
20
20
41
41
12
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-0.18
1.06
0.44
-0.14
0.14
-0.06
2.79
1.52
0.47
-0.21
-0.29
0.51
0.44
0.51
0.00

0.42
0.89
1.47
2.18
1.73
1.56
1.67
1.75
2.37
2.66
-0.23
0.29
0.34
1.46
1.84

binding. These fibrils gave much the same PGA1 binding results as
wild-type aside from a moderate binding improvement for the
unmodified cysteine mutant at residue 28 (Table 3). Removal of the
positive charge at residue 28 appears to have a positive impact on
PGA1 binding as seen for the K28C and K28C-MT fibrils. However, a
charge reversal due to CMT-modification eliminates the enhanced
binding (Table 3). The most interesting results from this work came
from PGA1 binding to the CMT-modified fibrils at residues 30 and 31
(alanine and isoleucine in wild-type). PGA1 binding to CMT-modified
A30C and I31C was quite good with ∆∆Gapp values around 2.8 kcal/mol
and 1.5 kcal/mol, respectively. These represent roughly ninety- and
ten-fold improved PGA1 binding affinity (Table 3, Figure 18b).
Replacement of these hydrophobic groups with a negatively charged
group seems to be beneficial to binding. In comparison, replacement
with the hydrophobic methyl group yielded little change in binding
affinity as seen in the binding results to the MT-modified fibrils (Table
3). From these data, it appears that PGA1 binding to Aβ fibrils is not
very sensitive to charge differences at residues 16 and 36. PGA1
binding appears to be sensitive to charge differences at residues 28,
30, and 31.
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Correlation Analysis
Several characteristics of anti-amyloid antibody binding to fibrils
were investigated through the aforementioned experiments. The salt
effects results suggest that electrostatic interactions are relatively
important to WO1 binding and hydrophobic interactions are relatively
unimportant. The pH results suggest that the interaction between
WO1 and fibrils is pH-optimized. This further supports the salt effect
results since electrostatic interactions are more sensitive to pH than
hydrophobic interactions. The WO1 and PGA1 binding results to the
many different mutant fibrils looked more closely into amyloid fibril
structure. None of the sets of mutants were complete, but there were
several noteworthy findings within the available binding results. WO1
binding to K16P fibrils and PGA1 binding to V36P fibrils was greatly
enhanced. Both WO1 and PGA1 binding to N27A and K28A fibrils were
significantly enhanced. PGA1 binding to A30C-CMT and I31C-CMT
fibrils was considerably enhanced while binding to K28C was
somewhat enhanced. These are the highlights of the results, but
much more information was made clear through comparisons of the
binding data to other available data.
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An issue mentioned in the results was that WO1 and PGA1 bound
comparably or better to most of the mutant fibrils compared to wildtype fibrils. This was somewhat unexpected since one would presume
the antibodies would bind significantly less strongly to at least some of
the mutant fibrils. A possible explanation for this bias could relate to
fibril stability. Most of the proline [34] and alanine (Angela Williams,
unpublished data) mutant fibrils were destabilized compared to wildtype fibrils. It could be that the antibodies are better able to bind
destabilized fibrils. This relationship could be considered in terms of
the fibril superstructure. Mutations causing fibril destabilization could
weaken the association of the protofilaments. This could result in
these protofilaments coming unwound at fibril ends like the frayed
ends of a rope. Frayed fibril ends could make the antibody binding
sites more accessible. The fibril stability data were compared to the
antibody binding data to look for any potential correlation (Figure 22,
Table 4). Antibody binding data were plotted versus fibril stability and
best fit lines were determined (Figure 22). Many different
comparisons were made, but no correlation was found between any
set of binding data and fibril stability (Table 4). It is possible that fibril
stability plays a role in antibody binding, but it does not appear to be
the dominant factor. A closer look at the data shows some overlap
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Figure 22. Comparison plots of antibody binding to fibril
stability. These plots are examples of the comparisons done for
antibody binding versus fibril stability. A best fit line was plotted for
each set of data and a correlation coefficient (R^2) found. The first
plot shown involves both WO1 and PGA1 binding to all the available
mutants including proline, alanine, and cysteine mutants. The other
two plots make more specific comparisons of subsets of the data.
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Table 4. Comparison table of antibody binding to fibril stability.
The first column lists all the different sets of antibody binding data
compared to different sets of fibril stability data. The second and third
columns show the slope and correlation coefficient (R^2) from the
best fit done for each set of data. The highest R^2 value was only
0.14. None of the comparisons showed any significant correlation.
Fibril stability comparison
Slope R^2
WO1/PGA1 to all mutants
0.1
0.008
WO1/PGA1 to all core mutants (15-36) 0.015 0.0003
WO1/PGA1 to pro mutants
0.18 0.022
WO1/PGA1 to ala mutants
-0.033 0.0013
WO1/PGA1 to core pro mutants (15-36) 0.029 0.0009
WO1/PGA1 to core ala mutants (15-36) -0.18 0.067
WO1 to pro/ala mutants
0.024 0.0004
PGA1 to pro/ala mutants
0.14 0.019
WO1 to core pro/ala mutants (15-36) -0.095 0.0087
PGA1 to core pro/ala mutants (15-36) 0.069 0.0073
WO1 to pro mutants
0.031 0.0005
PGA to pro mutants
0.32 0.071
WO1 to ala mutants
-0.052 0.0027
PGA1 to ala mutants
-0.02 0.0006
WO1 to core pro mutants (15-36)
0.095 0.0054
PGA to core pro mutants (15-36)
0.21 0.045
WO1 to core ala mutants (15-36)
-0.28
0.14
PGA1 to core ala mutants (15-36)
-0.083 0.018
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Between them (Figure 23). For the proline mutant fibrils, the data
overlap at residues 15, 16, 27, and generally 33 to 36 (Figures 23a &
b). For the alanine mutant fibrils, the data overlap at residues 27 and
28 (Figures 23c & d). These data include the mutant fibrils to which
the antibodies bound particularly well. This suggests that fibril
stability may have some impact on binding.

Another issue mentioned in the results is the importance of the
overall charge of the fibril or of certain residues within the Aβ
sequence. Considering all the mutant fibril binding data, it appears
that less positively charged or more negatively charged fibrils are
often bound better by the WO1 and PGA1 antibodies. This is
evidenced by anti-amyloid antibody binding to the K16P, K28A, K28C,
A30C-CMT, and I31C-CMT mutant Aβ fibrils. This is not always the
case such as for PGA1 binding to K16P, K16C, and K28C-CMT mutant
fibrils and for WO1 binding to K16A fibrils. Nonetheless, the charge of
these residues appears to have a strong impact on anti-amyloid
antibody binding. A comparison of the antibody binding data to
hydrophobicity change data was employed to further investigate these
results [46]. The binding data were compared to the change in
hydrophobicity due to the replacement of a wild-type residue with
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Figure 23. WO1 and PGA1 binding to proline and alanine
mutant fibrils versus fibril stability. The binding data were plotted
alongside proline and alanine mutant fibril stability data. A positive
fibril stability value indicates that the mutant is destabilized compared
to WT fibrils. A positive ∆∆Gapp value for antibody binding indicates the
antibody bound more strongly to the mutant fibrils than to WT fibrils.
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either proline or alanine. The hydrophobicity change data are based
on water/octanol partitioning of individual amino acids [46], so they
only approximate the change in the Aβ peptide. The hydrophobicity
change data were compared to the antibody binding data to look for
any potential correlation (Figure 24, Table 5). Antibody binding data
were plotted versus hydrophobicity change and best fit lines were
determined (Figure 24). Many different comparisons were made, but
no correlation was found for any of them (Table 5). This suggests that
WO1 and PGA1 binding do not correlate simply with the bulk
hydrophobicity or hydrophilicity of amyloid fibrils. However, there
does appear to be some correlation at certain residues. WO1 binding
data to the proline mutant fibrils coincides with the hydrophobicity
change data significantly at residues 16, 33, and 37 (Figure 25a).
Residue 16 was expected to stand out due to the positive charge and
highly hydrophilic nature of lysine. There was no correlation at residue
28, the other lysine to proline mutation. Perhaps substituting a rigid
proline at position 28 alters the fibril structure unfavorably for WO1
binding. Residues 33 and 37 are both glycines in wild-type Aβ.
Glycine is a somewhat hydrophilic, uncharged residue. WO1 may bind
more strongly to these mutants because of the increased
hydrophobicity or it may do so because of the significant structural
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Figure 24. Comparison plots of antibody binding to
hydrophobicity change. These plots are examples of the
comparisons done for antibody binding versus hydrophobicity change.
A best fit line was plotted for each set of data and a correlation
coefficient (R^2) found. The first plot shown involves both WO1 and
PGA1 binding to all the available proline and alanine mutant fibrils.
The other two plots make more specific comparisons of subsets of the
data.
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Table 5. Comparison table of antibody binding to
hydrophobicity change. The first column lists all the different sets
of antibody binding data compared to different sets of hydrophobicity
change data. The second and third columns show the slope and
correlation coefficient (R^2) from the best fit done for each set of
data. The highest R^2 value was only 0.25. None of the comparisons
showed any significant correlation.
Hydrophobicity comparison
Slope R^2
WO1/PGA1 to pro/ala mutants
0.36
0.02
WO1/PGA1 to core pro/ala mutants (15-36) 0.32 0.017
WO1/PGA1 to pro mutants
-0.15 0.0042
WO1/PGA1 to ala mutants
1.05
0.18
WO1/PGA1 to core pro mutants (15-36)
-0.26 0.013
WO1/PGA1 to core ala mutants (15-36)
1.04
0.22
WO1 to pro/ala mutants
0.47 0.028
PGA1 to pro/ala mutants
0.32 0.017
WO1 to core pro/ala mutants (15-36)
0.48
0.03
PGA1 to core pro/ala mutants (15-36)
0.23 0.011
WO1 to pro mutants
0.46 0.026
PGA to pro mutants
-0.62 0.067
WO1 to ala mutants
1.11
0.17
PGA1 to ala mutants
1.01
0.2
WO1 to core pro mutants (15-36)
0.53 0.034
PGA to core pro mutants (15-36)
-0.84
0.14
WO1 to core ala mutants (15-36)
1.1
0.2
PGA1 to core ala mutants (15-36)
1.01
0.25
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Figure 25. WO1 and PGA1 binding to proline and alanine
mutant fibrils versus hydrophobicity change. The antibody
binding data were plotted alongside hydrophobicity change data. The
hydrophobicity change data are based on water/octanol partitioning of
amino acids [46]. To calculate the change in hydrophobicity for each
mutant, the hydrophobicity value for either proline or alanine was
subtracted from that for the WT residue. A positive hydrophobicity
change value indicates increased hydrophobicity. A positive ∆∆Gapp
value for antibody binding indicates the antibody bound more strongly
to the mutant fibrils than to WT fibrils.
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change between the very flexible glycine and the rigid proline. The
PGA1 binding data to the proline mutant fibrils coincides with the
hydrophobicity change data at residues 16, 28, and 33 (Figure 25b).
Residues 16 and 28 were expected to stand out since they are both
lysines in wild-type fibrils. Residue 33 may stand out for the same
reasons discussed for WO1 binding. These results are revealing, but
the limitation that proline can substantially alter fibril structure must
be considered for these fibrils.

A comparison of antibody binding to hydrophobicity changes for
alanine mutant fibrils could be more informative since alanine should
not cause substantial structural changes. The WO1 and PGA1 binding
data to these fibrils coincides significantly with the hydrophobicity
change data only at residue 28 (Figures 25c & d). This suggests that
both antibodies bind more strongly to fibrils that are more hydrophobic
at this residue. The PGA1 binding data to the cysteine and modified
cysteine mutants at residue 28 support this notion (Table 3). There
was enhanced PGA1 binding to the more hydrophobic K28C and K28CMT fibrils, but not to the negatively charged K28C-CMT fibrils. These
results are further supported by studies of accessibility of cysteine
mutant fibrils to alkylation by iodoacetic acid (Dr. Shankaramma
123

Shivaprasad, unpublished data). These studies showed residue 28 to
be inaccessible to solvent, suggesting it is buried in the amyloid core.
If this is the case, a hydrophobic amino acid at this residue could
potentially stabilize the epitopes recognized by the antibodies.
Residues 16, 33, and 37 do not show a strong correlation as is seen
with the proline mutants (Figures 25c & d). This suggests that the
improved binding to the proline mutant fibrils at these residues may
be due to structural changes rather than simply increased
hydrophobicity. In the case of residue 16, it may be due to structural
changes rather than the removal of the positive charge.

The results for PGA1 binding to several mutants at residue 28
initially seem to run counter to the salt and pH effects experiments
(Figure 25, Table 3). The antibodies appear to prefer that residue 28
is hydrophobic. This would suggest that the antibodies bind through
hydrophobic interactions. However, residue 28 appears to be buried in
the amyloid core. Furthermore, PGA1 binding to mutants of residues
30 and 31 suggests electrostatic interactions are more important
(Table 3). There was greatly enhanced PGA1 binding to the negatively
charged A30C-CMT and I31C-CMT mutant fibrils, but not to the
unmodified or MT-modified fibrils. These results suggest PGA1 may
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rely more on electrostatic interactions. It is still likely that the binding
of PGA1 to fibrils is not entirely dependant on electrostatic
interactions. Nonetheless, PGA1 binding appears to be more
dependant upon electrostatic interactions.

There are many cases of enhanced antibody binding not
attributable to just charge or stability differences. These include WO1
binding to K16P and PGA1 binding to V36P fibrils (Figures 23 & 25). In
these cases, charge was not found to be important and fibril stability
was not drastically higher or lower than many mutant fibrils that were
bound less strongly by the antibodies. There may be specific
structural changes to these fibrils that make the antibody epitopes
more accessible or more favorable to the antibodies. For K16P and
V36P, one possible explanation is that the rigid proline could serve to
secure the unstructured amino- or carboxy-terminus such that it
cannot fold back onto the amyloid core. This may allow better
antibody access to the fibril surface. The enhanced binding of WO1
and PGA1 to N27A fibrils was unexpected. It does not appear to be
attributable to either a charge difference or a large stability difference
(Figures 23 & 25). These fibrils are destabilized, but not appreciably
more or less than many fibrils that were bound much less strongly by
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the antibodies. It appears that both WO1 and PGA1 binding are very
sensitive to changes at this residue. It could be that the structural
change, however small, imparted by substituting alanine for
asparagine stabilizes the epitopes recognized by the antibodies.

Another available set of data to which antibody binding can be
compared is ThT binding. These data were collected during the
monitoring of fibril growth progress for all of the mutant fibrils (Angela
Williams) [34]. The level of ThT binding is measured to detect the
amount of fibrils in a sample. Eventually, a maximal level of ThT
binding is obtained. This value is corrected based on the starting and
ending concentrations of Aβ monomer in a sample. The reason for this
correction is that ThT is measured on a fibril suspension that contains
varying percentages of fibrils, depending on the fibril stability
conferred by the mutation. ThT signal can be attributed to multiple
possible effects: ThT binding affinity, ThT binding site number, and/or
ThT fluorescent yield. It may be a combination of these three factors
affecting binding. This should be kept in mind when comparing the
antibody and ThT binding data. These two sets of data were compared
to look for any potential correlation between them (Figure 26, Table
6). Antibody binding data were plotted versus ThT binding data and
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Figure 26. Comparison plots of antibody binding to ThT
binding. These plots are examples of the comparisons done for
antibody binding versus ThT binding. A best fit line was plotted for
each set of data and a correlation coefficient (R^2) found. The first
plot shown involves both WO1 and PGA1 binding to all the available
proline and alanine mutant fibrils. The other two plots make more
specific comparisons of subsets of the data.
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Table 6. Comparison table of antibody binding to ThT binding.
The first column lists all the different sets of antibody binding data
compared to different sets of hydrophobicity change data. The second
and third columns show the slope and correlation coefficient (R^2)
from the best fit done for each set of data. The highest R^2 value was
0.42. None of the comparisons showed a strong correlation.
ThT fluorescence
Slope R^2
WO1/PGA1 to pro/ala mutants
0.48
0.11
WO1/PGA1 to core pro/ala mutants (15-36) 0.54
0.15
WO1/PGA1 to pro mutants
0.36 0.086
WO1/PGA1 to ala mutants
0.62
0.21
WO1/PGA1 to core pro mutants (15-36)
0.47
0.13
WO1/PGA1 to core ala mutants (15-36)
0.61
0.22
WO1 to pro/ala mutants
0.85
0.25
PGA1 to pro/ala mutants
0.37
0.12
WO1 to core pro/ala mutants (15-36)
1.04
0.34
PGA1 to core pro/ala mutants (15-36)
0.38
0.13
WO1 to pro mutants
0.55
0.15
PGA to pro mutants
0.31 0.063
WO1 to ala mutants
0.62
0.32
PGA1 to ala mutants
0.54
0.39
WO1 to core pro mutants (15-36)
0.93
0.33
PGA to core pro mutants (15-36)
0.33
0.07
WO1 to core ala mutants (15-36)
0.61
0.29
PGA1 to core ala mutants (15-36)
0.55
0.42
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best fit lines were determined (Figure 26). Many different
comparisons were made, but no strong correlation was found for any
of them (Table 6). However, overall the correlations were significantly
better than for the other attempted comparisons. There also appeared
to be correlation at certain residues. WO1 and ThT binding appeared
to have numerous connections within the set of proline mutants
(Figure 27a). The most prominent of these were at residues 16, 27,
and 33. Likewise, residues 16, 27, and 33 stood out notably for PGA1
binding (Figure 27b). These residues were earlier suggested to be
important for antibody binding due to possible structural changes
rather than to charge or major stability differences. It is possible that
ThT binding is similarly affected by these changes. WO1 and PGA1
binding to the alanine mutant fibrils appeared to overlap ThT binding,
particularly at residues 27, 28, and 29 (Figure 27c & d). These alanine
mutant fibrils are the most strongly bound by WO1 and PGA1. They
also represent three of the four alanine mutants most strongly bound
by ThT (Figure 27c & d). There are many parallels between the
binding of the antibodies and ThT to the alanine mutant fibrils. As
such, it is quite possible that the binding sites of the antibodies and
ThT are related. It is also possible that ThT and antibody binding both
correlate with an unknown third variable, such as fibril flexibility or
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Figure 27. WO1 and PGA1 binding to proline and alanine
mutant fibrils versus ThT binding. The antibody binding data were
plotted alongside ThT binding data. The ThT binding data are derived
from maximal corrected ThT fluorescence data obtained while
monitoring fibril growth (Angela Williams) [34]. These ThT data were
prepared for this comparison plot using the equation: (mutant ThT
fluorescence – WT ThT fluorescence) / WT ThT fluorescence. The ThT
data have no units. A positive ThT fluorescence change indicates
greater ThT binding by the mutant versus WT fibrils. A positive ∆∆Gapp
value for antibody binding indicates the antibody bound more strongly
to the mutant fibrils than to WT fibrils.
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Figure 27. Continued.
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24 25 26 27 28 29
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motility. In any case, there appears to be some connection between
the binding of the anti-amyloid antibodies and ThT to fibrils.

Antibody binding data were also compared to HD exchange data
for proline mutant fibrils [34]. These data provide a measure of the
amount of β-sheet structure since residues not involved in this
structure are expected to be more susceptible to HD exchange [34].
Comparing the binding data to these data could give some insight into
whether antibody binding correlates with the amount of β-sheet
structure. These two sets of data were compared (Figure 28, Table 7).
Antibody binding data were plotted versus HD exchange data and best
fit lines were determined (Figure 28). Several comparisons were
made, but no correlation was found for any of them (Table 7). This
suggests that WO1 and PGA1 binding do not correlate with the amount
of β-sheet structure implied by the HD exchange data.

After examining the antibody binding data and comparing it to
several other bodies of data, the information was compared to our
model of the amyloid protofilament (Figure 29a). In addition, it was
compared to another model of fibril structure with many differences
from our model [47] (Figure 29b). The Tycko model consists of Aβ
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WO1 and PGA1 binding versus change in protected
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Figure 28. Comparison plots of antibody binding to difference
in protected residues. These plots are examples of the comparisons
done for antibody binding versus the number of protected residues
above WT fibrils. These numbers were calculated from the data
presented in [34] using the equation: (40 - # protected residues in
mutant) - # protected residues in WT. A best fit line was plotted for
each set of data and a correlation coefficient (R^2) found. The first
plot shown involves both WO1 and PGA1 binding to all the available
proline mutant fibrils. The second plot involves WO1 binding only.
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Table 7. Comparison table of antibody binding to difference in
protected residues. The first column lists all the different sets of
antibody binding data compared to different sets of HD exchange data.
The second and third columns show the slope and correlation
coefficient (R^2) from the best fit done for each set of data. The
highest R^2 value was 0.071. None of the comparisons showed any
correlation.
HD exchange comparison
Slope R^2
WO1/PGA1 to pro mutants
-0.17 0.0054
WO1/PGA1 to core pro mutants (15-36) -0.38 0.024
WO1 to pro mutants
0.056 0.0003
PGA to pro mutants
-0.2 0.0087
WO1 to core pro mutants (15-36)
-1.14 0.071
PGA to core pro mutants (15-36)
-0.23 0.011
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Figure 29. Two Aβ amyloid protofilament models. Our model is
shown in figure A while the Tycko model [47] is shown in figure B.
(Figure B adapted from Petkova, A.T., et al., A structural model for
Alzheimer's beta -amyloid fibrils based on experimental constraints
from solid state NMR. Proc Natl Acad Sci U S A, 2002. 99(26): p.
16742-7.)
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subunits in which there are two β-strands, residues 12 to 24 and 30 to
40. The amino terminus is unstructured and residues 25 to 29
comprise a bend in the sequence [47]. There is also a potential salt
bridge between residues D23 and K28 in the core of the Tycko model
(Figure 29b).

The possible explanation for the WO1 binding results to K16P
could fit into either model. That is, the rigid proline could serve to
secure the unstructured amino-terminus such that it does not fold
back onto the fibril and impede the antibody from binding. In both
cases, there is an unstructured amino-terminus, though this terminus
stops around residues 10 to 12 in the Tycko model (Figure 29b). The
results for PGA1 binding to V36P can be similarly explained as this
residue is near the unstructured carboxy-terminus in our model
(Figure 29a). They do not, however, fit as well into the Tycko model
since it lacks an unstructured carboxy-terminus. It is possible that
these results could hinge more on destabilization of the fibril. If that is
case, they could fit the Tycko model.

The results for WO1 and PGA1 binding to N27A are less clear.
The change from an asparagine to an alanine does not result in a
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charge difference and should not cause large structural changes
compared to wild-type. In our model, this residue is in the middle of a
β-strand whereas in the Tycko model it is in the bend between the two
β-strands (Figure 29). The results for residue 27 do not seem to
exclude either model. However, they do not seem to clearly support
one over the other either.

The results for PGA1 binding to the A30C-CMT mutant fibrils
could fit into either model. Both models transition from turn to βstrand structure around this residue. Being near the turn region,
charged residues may be tolerated or, as the binding data suggests,
preferred. Residue 30 appears to be extremely accessible to solvent
based on the cysteine mutant fibril alkylation studies (Dr.
Shankaramma Shivaprasad, unpublished data). Those results are in
agreement with both models [34, 47]. The PGA1 binding results to
the A31C-CMT mutant fibrils are somewhat less clear. This residue
appears to be inaccessible to solvent based on the aforementioned
alkylation studies (Dr. Shankaramma Shivaprasad, unpublished data).
Furthermore, it is buried in the core of the Tycko model [47]. The
results do not seem to fit either model. These fibrils may possess an
altered structure, such as incorporating residues 30 and 31 into an
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extended turn, to accommodate a charge at this residue. It could also
be the case that the residue is still in the fibril core at the cost of
reduced fibril stability. The latter scenario takes into account that
PGA1 appears to bind more strongly to destabilized fibrils.

The results for WO1 and PGA1 binding to K28A fibrils seem quite
clear. Combined with the PGA1 binding results to modified cysteine
mutant fibrils, it appears that the antibodies bind more strongly to
fibrils in which residue 28 is hydrophobic. Residue 28 appears to be
buried in the amyloid core, a hydrophobic environment unfavorable to
lysine. A more hydrophobic amino acid at this position could
potentially pack better into the amyloid core. This could stabilize the
epitopes recognized by WO1 and PGA1. The Tycko model has the
lysine at residue 28 in the amyloid core, but it may form a salt bridge
with the aspartic acid at residue 23 [47] (Figure 29b). Residue 23
appears to be inaccessible to solvent based on the aforementioned
alkylation studies (Dr. Shankaramma Shivaprasad, unpublished data).
This lends some support to the Tycko model. However, the antibody
binding results to the mutants at residue 28 seem to indicate that if a
salt bridge exists, it is not critical to the structure of the fibril. A salt
bridge may exist in wild-type fibrils, but the K28A mutant may prevent
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it forming. This could alter fibril structure, possibly to the benefit of
antibody binding.

Conclusions
Several characteristics of anti-amyloid antibody binding to fibrils
were investigated. The salt and pH effects results suggest that
electrostatic interactions are relatively important to WO1 binding and
hydrophobic interactions are relatively unimportant. The WO1 and
PGA1 binding results to the many different mutant fibrils looked more
closely into amyloid fibril structure. There were several noteworthy
findings. WO1 binding to K16P fibrils and PGA1 binding to V36P fibrils
was greatly enhanced. Both WO1 and PGA1 binding to N27A and
K28A fibrils were significantly enhanced. PGA1 binding to A30C-CMT
and I31C-CMT fibrils was considerably enhanced while binding to K28C
was somewhat enhanced.

Much more information was made clear through comparisons of
the binding data to other available data. A comparison of the binding
data to fibril stability showed no correlation. Fibril stability could play
a role in antibody binding, but it does not appear to be the dominant
factor. Antibody binding data were compared to hydrophobicity
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change data, but no correlation was found. This suggests that WO1
and PGA1 binding do not correlate with the bulk hydrophobicity or
hydrophilicity of amyloid fibrils. Antibody binding data were compared
to HD exchange data to look for a relationship between the amount of
β-sheet structure and binding. No correlation was found, suggesting
that WO1 and PGA1 binding do not correlate with the amount of βsheet structure implied by the HD exchange data. Comparing antibody
and ThT binding data to fibrils revealed some weak correlation. This is
the most interesting result to come from the correlation studies. It
suggests there could be a relationship between binding of the antiamyloid antibodies and ThT to fibrils.

With regard to certain residues, there appeared to be more
correlation. Fibril stability appears to show some importance to
antibody binding with regard to certain residues such as 16 and 36.
Charge also appears to be important considering the results at
residues 28, 30, and 31. In addition, some more specific structural
features appear to be important based on the results at residues 16,
27, and 36. It looks as if the binding of these antibodies and ThT to
amyloid fibrils are related based on some correlation in the data
overall and some overlap in the binding results to specific mutants. It
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does not appear that antibody binding correlates with the amount of βsheet structure implied by the HD exchange data. Lastly, the binding
results agree, for the most part, with our model of Aβ amyloid.
Mutations in the Aβ sequence have a strong impact on binding of the
anti-amyloid antibodies. The basis of these results is still not clear,
but they could be important clues to the nature of fibril structure or at
least the fibril epitopes recognized by the antibodies.
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Chapter IV
Phage Display Results and Discussion

The available anti-amyloid antibodies are all of the IgM class
(Figure 5e). As mentioned earlier, these are large, flexible,
multivalent species not amenable to many structural studies. For
example, the large size and flexibility of IgM molecules is very
unfavorable to protein crystallography. Another example is the
multivalent and cooperative nature of IgM binding to antigens
complicates potential mutagenesis studies because a single mutation
affects all ten binding sites. One potential option is to study fragments
of these IgM antibodies. However, it was shown that monovalent
fragments of WO2 do not bind any better to Aβ fibrils than to BSA
(Figure 14). It would be preferable to study fragments with significant
affinity for amyloid fibrils. Due to the limitations of the available
antibodies, phage display experiments were carried out with the goal
of producing anti-amyloid antibody fragments. Some progress was
made to this end.
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Verification of Phage Production and Anti-M13 Antibody
Specificity
The phagemid clone received from the Barbas laboratory was
transformed into XL1-Blue E. coli cells. A culture of the transformed
cells was grown up and infected with helper phage to produce clonal
phage particles. These were purified for use in a preliminary phage
ELISA. This experiment was conducted to determine three things: if
the phage production protocol generates a suitable phage titer, if the
phage clone is bound by the chosen anti-M13 biotin secondary
antibody, and if there is any significant background binding of the
secondary antibody to Aβ amyloid. There appeared to be a suitable
phage titer and strong binding by the secondary antibody. This is
evidenced by the substantial binding curve for anti-M13 antibody to
the phage clone (Figure 30). There is essentially no background
binding of anti-M13 antibody to Aβ amyloid evidenced by a flat curve
(Figure 30).

Phage Library Production
To generate the initial phage library, PCR random mutagenesis
was carried out on the Fab genes within the phagemid clone.

As

stated earlier, 6 clones were selected for sequencing with the OMPSEQ
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Verification of anti-M13 Ab specificity
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Figure 30. Verification of anti-M13 Ab specificity. The blue
diamond marked curve shows that the purified phage clone is bound
by the anti-M13 antibody. The magenta square marked curve is a
positive control to verify the activity of the anti-M13 antibody on
immobilized phage. The green triangle marked curve shows the lack
of significant background binding by the anti-M13 antibody to amyloid
fibrils.
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primer (Table 2) to determine the rate of mutagenesis. The rate of
base mutation was found to be roughly 1.5%. The phagemid library
was transformed into XL1-Blue E. coli cells. Three rounds of selection
against Aβ amyloid were conducted in hopes of enriching phage
capable of binding the fibrils. The input and output phage titers at
each stage of panning were determined. The phage titer after
transformation of the starting library was 5*10^8 pfu/mL. For pan 1,
the titers were 3*10^12 pfu/mL input and 2*10^7 pfu/mL output.
For pan 2, the titers were 8*10^11 pfu/mL input and 8*10^2 pfu/mL
output. For pan 3, the titer could not be determined since all of the
plates were blank, including the input titer plates. Phage pools from
each round of selection as well as a nonpanned, preselection pool were
saved for a total of four phage pools.

To test the phage pools for the presence of Aβ amyloid binding
clones, several phage ELISA experiments were performed. All four
phage pools were tested using the anti-M13 phage antibody as the
secondary antibody. These experiments were not meant to be used
for determining binding activity, but just to confirm whether or not
there is any significant binding at all. This is indicated by a higher,
right-shifted curve for aggregate binding compared to background
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binding to BSA. The phage ELISAs indicated that all the phage pools
possessed the ability to bind Aβ amyloid (Figure 31). This was
unexpected since even the nonpanned phage pool appeared to possess
affinity to Aβ amyloid fibrils (Figure 31, top left). These results
indicate that there are a large number of binders even before
selection. Antigen-binding sites are normally formed from the CDRs,
but random mutagenesis should not favor these regions over the rest
of the sequence. The majority of the mutants are likely structurally
altered with truncations and mutations in antibody framework regions.
Considering the markedly better affinity of the nonpanned library for
fibrils over BSA blocked wells, it is possible that much of the binding
came from such structurally altered antibodies. This suggests there
could be considerable nonspecific binding. Phage ELISAs were also
conducted against polyglutamine aggregates and the phage pools were
found to have an affinity for them as well (Figure 31, bottom). Again,
this may be due to nonspecific binding. Clones were ultimately
selected from all four pools and tested against both Aβ amyloid and
polyglutamine aggregates.
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Figure 31. Phage pool ELISAs. ELISA binding assays were
conducted using phage pools in place of the primary antibody. Even
the nonpanned pool shows Aβ amyloid binding (top left). There is also
binding to polyglutamine aggregates, even though the library was
selected against Aβ amyloid (bottom).
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Phage Clone Selection
The cultures from which the phage pools were collected were
plated and several clones were selected from each. Cultures were
inoculated with picked colonies and grown up to produce clonal phage
particles. The same was done for the unmutated phage. Phage
ELISAs were carried out for each to determine if any of these
individual clones could bind Aβ amyloid. Including the unmutated
clone, 25 clones were tested for Aβ amyloid binding and 6 clones for
polyglutamine aggregate binding. 10 clones from the nonpanned pool,
10 from the first panning, 2 from the second panning, and 2 from the
third panning were tested for binding to Aβ amyloid. 2 of 25 bound Aβ
amyloid more strongly than BSA: clones 1-1 and 2-2 (Figure 32). 4 of
6 drawn from the same set of clones bound polyglutamine aggregates
more strongly than BSA: clones 1-1, 2-1, 2-2, and 3-1 (Figure 33).
The unmutated clone did not bind either aggregate very well,
especially when compared to the clones in figure 33. The problem
with most of the clones binding to Aβ amyloid was that their binding to
BSA was comparable (Figure 32, bottom right). With the
polyglutamine aggregates, this was not an issue. Four clones were
selected for further work. These are designated 1-1, 2-1, 2-2, and 31. The first number stands for the pool from which the clone was
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Figure 32. Phage clone binding to Aβ amyloid fibrils. The
unmutated clone showed essentially no binding. Clones 1-1 and 2-2
are the only two positive clones obtained. Clone 3-2 is an example of
one of the rejected clones. For this clone and most of the other
negative clones there was often binding to Aβ amyloid, but there was
also comparable binding to BSA.
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Figure 33. Phage clone binding to polyglutamine aggregates.
ELISA binding curves using phage clones in place of the primary
antibody. The top 3 curves are for Aβ amyloid binding and the bottom
5 are for polyglutamine aggregate binding.
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taken. For example, clone 2-1 is from the second panning pool.
Clones 1-1 and 2-2 bound to both Aβ amyloid and polyglutamine
aggregates (Figures 32 and 33). Clones 2-1 and 3-1 bound to
polyglutamine aggregates only (Figure 33). The amino acid sequences
of these clones were examined to look for any differences from the
original, unmutated clone.

Antibody Clone Sequences
Cultures were grown up for each clone, including the unmutated
clone. Plasmid preparations were performed and the plasmids were
sent off for sequencing using the OMPSEQ and PELSEQ primers (Table
2). The DNA sequences were translated to amino acid sequences.
The heavy and light chain amino acid sequences for the clones are
shown in tables 8 and 9, respectively. It is clear from the data that
most of the clones are actually truncation mutants. The clone 2-1
heavy chain sequence is the only one besides the unmutated heavy
and light chains that is not truncated (Tables 8 and 9). It actually has
an identical amino acid sequence to that of the unmutated heavy
chain. Two sequences were truncated as a result of a stop codon
introduced by a substitution mutation: clone 1-1 heavy chain and
clone 3-1 light chain. Three sequences were truncated as a result of
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Table 8. Clone heavy chain sequences. Only the clone 2-1 heavy
chain lacks a truncation mutation. Clone 2-2 appeared to actually be
multiple clones by examining the electropherogram (data not shown).
Therefore, the clone 2-2 sequence data could not be translated.
Residues differing from unmutated are bold, italic, and highlighted in
red.
ORF
Clone
Sequence
length
MAEVQLLEQSGAEVKKPGSSVKVSCRASGGTF
NNYAISWVRQAPGQGLEWMGGIFPFRNTAKY
AQHFQGRVTITADESTGTAYMELSSLRSEDTAI
YYCARGDTIFGVTMGYYAMDVWGQGTTVTVS
258
Unmutated AASTKGPSVFPLAPSSKSTSGGTAALGCLVKDY
FPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS
LSSVVTVPSSSLGTQTYICNVNHKPSNTKVDK
KVEPKSCDKTSGQAGQHHHHHHGAYPYDVPD
YAS
MAEVQLLEQSGAEVKKPGSSVKVSCRASGDTF
1-1
64
NNYAISWVRQAPGQGLEWMGGFFPFLYTAKY
A
MAEVQLLEQSGAEVKKPGSSVKVSCRASGGTF
NNYAISWVRQAPGQGLEWMGGIFPFRNTAKY
AQHFQGRVTITADESTGTAYMELSSLRSEDTAI
YYCARGDTIFGVTMGYYAMDVWGQGTTVTVS
258
AASTKGPSVFPLAPSSKSTSGGTAALGCLVKDY
2-1
FPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS
LSSVVTVPSSSLGTQTYICNVNHKPSNTKVDK
KVEPKSCDKTSGQAGQHHHHHHGAYPYDVPD
YAS
2-2
--MAEVQLLEQSGAEVKKPGFSVKVSCRASGGT
3-1
85
STIMPSAGCDRPLDKGLSGWEGSSLSVIQ
QSTHNTSRAESPLPRTNPRAQPTWS
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Table 9. Clone light chain sequences. All the clones were
apparently truncation mutants. Clone 2-2 appeared to actually be
multiple clones (data not shown). Residues differing from unmutated
are bold, italic, and highlighted in red.
ORF
Clone
Sequence
length
MAGFATVAQAAELTQSPGTLSLSPGERATLSC
RASHSVSRAYLAWYQQKPGQAPRLLIYGTSSR
ATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYY
223
CQQYGGSPWFGQGTKVELKRTVAAPSVFIFPP
Unmutated
SDEQLKSGTASVVCLLNNFYPREAKVQWKVD
NALQSGNSQESVTEQDSKDSTYSLSSTLTLSK
ADYEKHKVYACEVTHQGLSLPVTKSFNRGEC
MAGFATVAQAAELTQSPGTLSLSPGERAPSPA
1-1
42
GPVTVLAGPT
MAGFATVAQAAELTQSPGTLSLSPGESHPLLQ
2-1
37
GQSQC
2-2
--MAGFATVAQAAELTQSPGTLSLSTGERASLSC
3-1
41
WASLSISRA
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insertions or deletions causing frameshifts that subsequently led to
premature stop codons: 3-1 heavy chain, 1-1 light chain, and 2-1
light chain. The clone 2-2 heavy and light chain sequences could not
be accurately translated. An examination of the electropherograms of
these two sequences revealed numerous occurrences of overlapping
base peaks (data not shown). This suggests there is more than one
clone in the clone 2-2 sample.

Unfortunately, not all the clone sequences appear to agree with
the binding results. The clone 1-1 and 3-1 heavy chains are both
truncated (Table 8). This has been verified by obtaining these
sequences a second time. The downstream gp3 segment of these
fusion proteins are, as a result, not expressed (Figure 11). Lacking
this segment, the antibody fragment would not be associated with the
phage particle and should not have an impact on phage selection.
Since phage expressing these clones appeared to bind amyloid, it
seems that the phage clones could be binding nonspecifically. Clones
1-1 and 3-1 are apparently false positives. Though the 2-1 light chain
is truncated due to a frameshift mutation, the heavy chain is intact.
This clone could be detected via an anti-HA western blot. Soluble
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expression was attempted for all the clones including the unmutated
clone.

Soluble Expression
Fresh E. coli cultures expressing each phagemid were
grown up and plasmid preps were used to purify the clonal phagemid
DNA. These phagemid were electroporated into TOP10 E. coli cells in
order to carry out expression of soluble Fab protein. Whole protein
extracts were taken from cultures of these clones and tested for the
presence of Fab protein using western blots. Two monoclonal anti-HA
antibodies were used in one set of western blot experiments and a
polyclonal anti-human heavy and light chain antibody in another. The
anti-HA western blot results lined up with the sequencing results
(Figure 34). As expected, only the two clones possessing the HA tag,
the unmutated clone and clone 2-1, showed up on these blots.
Cultures expressing the clones were grown up for protein extraction
and western blots several times, but these clones did not show strong
bands on every blot. In figure 34, the umutated clone showed
stronger bands in blot A while clone 2-1 showed a stronger band in
blot B. It may be that the Fab fragments are not stably expressed
under the culture conditions used. It is also possible that the HA tag
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A

Figure 34. Anti-HA western blots. The lanes in western A are as
follows: 1) anti-HA IgG, 2) blank, 3) unmutated, 4) clone 3-1, 5)
clone 2-2, 6) clone 2-1, 7) clone 1-1, 8) unmutated from another
culture, 9) untransformed, 10) Seeblue Plus 2 MW standard
(Invitrogen). The lanes in western B are as follows: 1) clone 2-1, 2)
unmutated, 3) human IgG, 4) clone 3-1, 5) clone 2-2, 6) clone 2-1, 7)
clone 1-1, 8) unmutated from another culture, 9) same as lane 8, 10)
Seeblue Plus 2 MW standard.
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B

Figure 34. Continued.
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located at the carboxy-terminus of the heavy chain could have been
cleaved before loading the samples onto the gels. For the unmutated
and 2-1 clones, the strong band was at approximately the correct
molecular weight to represent a heavy chain Fd fragment, around 25
kDa (Figure 34). There were different background bands in each of
these two blots. This may be due to the different anti-HA antibodies
used.

The anti-human IgG (heavy and light chain specific) western blot
showed bands around 25 kDa for some of the clones (Figure 35).
There were also bands near the gel front for all the clones. The latter
bands may represent truncated or partially degraded light and heavy
chain fragments. The blot in figure 34b was run alongside that in
figure 35, but the results were not consistent. The band near 25 kDa
for clone 2-1 was very faint. Furthermore, this band was present for
clone 3-1, a truncation mutant that should not have it. The antihuman IgG western blot results were not consistent. However, the
anti-HA western blot results show that if an intact clone is available,
expression can be achieved.
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Figure 35. Anti-human IgG (heavy and light chain specific)
western blot. The lanes in the western are as follows: 1) clone 2-1,
2) unmutated, 3) human IgG, 4) clone 3-1, 5) clone 2-2, 6) clone 2-1,
7) clone 1-1, 8) unmutated from another culture, 9) same as lane 8,
10) Seeblue Plus 2 MW standard.
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Conclusions
Initial phage ELISA results suggested that the phage libraries,
including nonpanned, had an affinity for amyloid fibrils. However, an
examination of sequences of selected positive clones revealed that the
phage selection procedure was ineffective. All the clones possessed
truncations in the antibody heavy chain, the light chain, or both. This
suggests that these clones were binding nonspecifically. The
unmutated clone and clone 2-1 were expressed as soluble fragments,
but were not purified for further analysis. Further work will need to be
done to obtain anti-amyloid Fab fragments.

A successful strategy for obtaining truly positive clones could
include a step to select for those phage presenting intact Fab
fragments. One way to do this could be to include an additional
selection step in which the phage are incubated in ELISA wells coated
with anti-Fab antibodies. That is, after the selection step against
amyloid, the library could be reamplified and subjected to Fab
selection before continuing with the next round. This step could enrich
the library with clones presenting intact Fab fragments and reduce the
number of false positives during the screening process that follows
selection.
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Appendix I
1% BSA in 1xPBS:
1g
100 mL

BSA (Sigma)
1xPBS (Fisher)

For 3% or 5% BSA, add 3 g or 5 g of BSA, respectively.
1xPBS:
140 mM NaCl, 10 mM Na2PO4, 2.2 mM KH2PO4, 2.7 mM KCl
Order from Fisher as a pre-weighed powder. Mix into 1L water and
filter for a 10x stock solution. Dilute to 1x in water and filter before
use.
cell suspension buffer:
2.5 mL
2.5 mL
95 mL

0.2 M EDTA, pH 8.0 (Sigma)
1.0 M Tris, pH 7.5 (Sigma)
water

ELISA blocking solution:
1g
100 mL
50 µL

BSA
1xPBS
Tween20 (Fisher)

ELISA wash buffer:
500 mL
250 µL

1xPBS
Tween20
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LB agar:
8g

Difco LB agar (Beckton Dickinson)

Add water to 250 mL final volume. Autoclave for 20 minutes at 15 psi.
Let cool to about 45°C. Pour about 25 mL into each plate and allow
the agar to set for at least 2 hours before use.
LB agar+tetracycline:
Prepare LB agar, but do not immediately pour into plates after cooling
to 45°C. Add tetracycline (Sigma) to a final concentration of 12
µg/mL, 600 µL of 5 mg/mL tetracycline, and rotate gently to mix.
Pour plates.
LB agar+carbenicillin:
Prepare LB agar, but do not immediately pour into plates after cooling
to 45°C. Add carbenicillin (Sigma) to a final concentration of 50
µg/mL, 125 µL of 100 mg/mL carbenicillin, and rotate gently to mix.
Pour plates.
25% PEG-8000 / 15% NaCl:
25 g
15 g

PEG-8000 (Sigma)
NaCl

Add water to 100 mL final volume. Stir on a hot plate to dissolve
solids. Autoclave for 20 minutes at 15 psi.
SB medium:
5g
15 g
10 g

MOPS (Sigma)
tryptone (Fisher)
yeast extract (Beckton Dickinson)

Add water to 500 mL final volume. Adjust pH to 7.0 with sodium
hydroxide. Autoclave for 20 minutes at 15 psi.
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SOC medium:
1g
0.25 g
0.025 g
9.3 mg

tryptone
yeast extract
NaCl
KCl

Add water to 50 mL final volume. Adjust pH to 7.0 with sodium
hydroxide. Autoclave for 20 minutes at 15 psi.
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